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Abstract 
The stroke prone spontaneously hypertensive rat (SHRSP) is an excellent inbred 
model  of  cardiovascular  disease.  Previous  work  in  our  laboratory  utilising 
chromosome  14  congenic  strains  confirmed  a  quantitative  trait  locus  for  left 
ventricular mass index.  The aims of this project were to use gene expression 
profiling  in the heart  during  the  development of  left  ventricular  hypertrophy 
(LVH) to identify positional candidate genes within the congenic interval. Exon 
analysis  identified  significant  differential  expression  of  Chemokine  ligand  13 
(Cxcl13)  in  5  week  old  SHRSP,  WKY  and  respective  chromosome  14  congenic 
strains.    After  validation  by  qRT PCR,  DNA  sequencing  and  Transfac  analysis 
implicated  the  loss  of  Hepatocyte  Nuclear  Factor  4  in  the  SHRSP.    Illumina 
analysis  identified  differential  expression  of  Osteopontin  (Spp1)  in  neonatal 
hearts of the SHRSP versus WKY and respective chromosome 14 congenic strains 
as a positional candidate gene.  The identification of these positional genes prior 
to the onset of hypertension may identify novel mechanisms in the development 
of LVH in the SHRSP. 3 
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Summary 
Left  ventricular  hypertrophy  (LVH)  is  accepted  as  an  important  independent 
predictor of adverse cardiovascular outcome; the aetiology includes a number of 
well recognized  causes  but  there  is  considerable  interest  in  the  genetics 
underlying cardiac hypertrophy.  The stroke prone spontaneously hypertensive 
rat (SHRSP) is an excellent inbred model of cardiovascular disease.  Previous 
work within the laboratory identified a quantitative trait locus (QTL) for left 
ventricular  mass  index  (LVMI)  on  chromosome  14,  and  congenic  strains 
(SP.WKYGla14a  &  WKY.SPGla14a)  on  both  the  SHRSP  and  WKY  genetic 
backgrounds were constructed.  SNP genotyping in the SHRSP and WKY strains 
confirmed the microsatellite genotyping data and identified SNP’s principally to 
a 29Mbp region (between 5 34Mbp) on chromosome 14 confirming the LVMI QTL 
data.  The remaining region of chromosome 14 was identical by descent in the 
SHRSP and WKY.   
Affymetrix exon array was carried out in collaboration with Klio Maratou & Tim 
Aitman  using  RNA  from  the  5  week  old  hearts  in  the  SHRSP,  WKY  and 
chromosome 14a congenic (SP.WKYGla14a & WKY.SPGla14a) strains.  A number 
of analysis strategies were implemented including exon level, gene level and 
alternate  splicing.    Genome wide  analysis  did  not  yield  any  significant 
differences across all 4 strains at the exon or the gene level analyses.  However, 
filtering  the  analysis  specifically  to  the  29Mbp  minimum  congenic  interval  of 
chromosome 14 identified 59 exons, representing 14 annotated genes in the exon 
analysis, and 2 genes (Cxcl13 & Abcg3) in the gene level analysis.  Furthermore 
alternative splicing implicated 6 genes including the Clock gene.  The exon array 
identified the Clock gene as a potential candidate, but it was suggested that a 
SNP in the open reading frame had led to the difference in signal intensity in the 
array, as the probe was not able to hybridize to the cRNA on the chip efficiently.  
Gene level analysis identified Cxcl13 and Abcg3 as positional candidate genes, 
and analysis using qRT PCR confirmed Cxcl13 as being differentially expressed 
across the 4 strains.  Further analysis utilising PCR and sequencing has identified 
a SNP in the 5’ promoter region and 2 SNP’s in the 3’ UTR.  Transcription factor 
analysis of the 5’ promoter region SNP implicated the loss of Hepatocyte Nuclear 
Factor  4  (HNF4)  in  the  SHRSP.    We  extended  the  analysis  on  the  Illumina 11 
platform to include neonatal, 5 week and 16 week old parental and chromosome 
14a congenic animals.  This allowed for the identification of positional candidate 
genes, prior to the onset of hypertension and cardiac hypertrophy.  Genome 
wide  gene  expression  profiling  on  the  Illumina  platform  was  generated  using 
neonatal, 5 week & 16 week old animals.  Focus was placed on the neonatal 
time  point,  and  analysis  identified  4  differentially  expressed  genes  including 
Osteopontin  (Spp1)  as  a  positional  candidate  gene  in  neonatal  hearts  of  the 
SHRSP vesus WKY and the reciprocal chromosome 14a congenic strains.  This was 
validated by qRT PCR, and further analysis of the gene through DNA sequencing 
identified 2 SNP’s in the 5’ promoter region and 2 SNP’s in the ORF.  Primer 
design  of  the  poorly  annotated  5’  upstream  region  of  Spp1  in  the  rat  was 
enabled  by  the  alignment  of  7  other  mammalian  strains  to  identify  areas  of 
homology.   
Primary cardiomyocytes and fibroblasts were isolated for functional analysis of 
hypertrophy  and  migration/proliferation  in  the  cells.    Cardiomyocytes  were 
identified as the source of increased expression of Spp1.  ANG II stimulation of 
cardiomyocytes led to an increase in cell size in the SHRSP and WKY, but did not 
significantly increase Spp1 expression levels in these strains.  Migration assay 
implicated  the  WKY.SPGla14a  cardiac  fibroblasts  as  having  an  increased 
migration potential compared with WKY cardiac fibroblasts, which may indicate 
their role in fibrosis of the heart.   The results were validated by performing an 
MTT assay to measure proliferation of the cells, to ensure it is migration, not 
proliferation which is causing this effect.   
This  highlights  Spp1’s  potential  for  further  work  as  an  excellent  positional 
candidate gene. 12 
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1 Introduction Wendy Crawford    16 
Cardiovascular Disease 
1.1  Human Cardiovascular Disease 
Cardiovascular disease (CVD), also known as heart and circulatory disease, is the 
biggest killer in the UK, and is responsible for 38% of all deaths.  It includes 
conditions such as coronary heart disease (CHD)   angina and heart attack, and 
stroke.  Approximately half of all deaths from CVD in the UK are from CHD and 
about a quarter are from stroke, around 53,000 every year.  Stroke is second 
only to coronary heart disease as the biggest killer in the UK and is also a major 
cause of premature mortality, responsible for over 9,500 deaths every year in 
people under the age of 75, about one in twenty of all deaths in this age group.  
The  incidence  of  stroke  increases  rapidly  with  increasing  age.  (British  Heart 
Foundation statistics, 2010).   
1.1.1   Blood Pressure control 
Blood  pressure  is  the  force  which  allows  blood  to  flow  through  the  arteries, 
capillaries, reaching all the organs, before returning to the heart via the veins.  
It is of great importance that it is finely regulated, as the blood is relied on to 
deliver  oxygen,  nutrients  and  hormones,  all  within  acceptable  rates,  and  to 
subsequently clear the waste products generated by body’s normal processes.  
Blood pressure (or mean arterial blood pressure) is defined as the rate of blood 
flow produced by the heart (cardiac output) multiplied by the resistance of the 
blood  vessels  to  blood  flow  (vascular  resistance).  This  resistance  is  produced 
mainly in the arterioles and is known as the systemic vascular resistance (SVR) or 
the peripheral vascular resistance (PVR), hence, mean arterial blood pressure. 
Mean arterial blood pressure requires a number of physiological mechanisms to 
maintain a normal blood pressure, which ensures an adequate perfusion to the 
body tissues, and incorporates a number of integrated systems within the body 
for  this  function.    The  main  organ  used  is  the  kidney,  as  it  regulates  blood 
volume by controlling salt and water levels. Wendy Crawford    17 
1.1.1.1  The renin angiotensin aldosterone system 
The renin angiotensin aldosterone system is the major mechanism responsible 
for blood pressure control.  It requires a number of hormones, and the most 
studied elements of this system are the angiotensin converting enzyme (ACE), 
and angiotensin II (ANG II).  When a fall in blood pressure, or decrease in serum 
sodium  chloride  (NaCl)  is  detected,  the  juxtaglomerular  cells  of  the  kidney 
secrete  renin.    Angiotensinogen,  is  an  inactive  α 2 globulin  produced  by  the 
liver, which is produced constitutively, and released into plasma circulation.  It 
is  converted  to  Angiotensin  I  (ANG  I)  by  the  cleavage  of  the  peptide  bond 
between the leucine and valine residue, mediated by the enzyme renin.  ANG I 
has no other biological activity, other than to act as a precursor for ANG II.  The 
conversion of ANG I to ANG II is mediated by ACE, which is found predominantly 
in  the  capillaries  of  the  lung.    ANG  II  is  a  vasoconstrictor  which  results  in 
increased blood pressure.  It also stimulates the release of aldosterone from the 
adrenal  cortex,  which  leads  to  sodium  and  chloride  re absorption  and  water 
retention.    It  also  stimulates  the  release  of  anti diuretic  hormone  (argenine 
vasopressin  ADH),  a  vasoconstrictor,  which  leads  to  an  increase  in  water 
retention in the collecting ducts (Figure 1.1).  ANG II is also involved in other 
mechanisms, such as decreasing medullary flow which lowers the NaCl and urea 
washout,  facilitating  increased  re absorption.    It  also  stimulates  renal 
hypertrophy, which leads to further sodium re absorption (reviewed by Paul M et 
al, 2006).   
 Wendy Crawford    18 
 
Figure 1.1 The renin angiotensin aldosterone system 
The  mechanism  whereby  blood  pressure  is  regulated  by  hormones  and  enzymes  to 
maintain pressure within normal physiological limits. 
1.1.1.2  Other mechanisms of Blood Pressure control 
The autonomic nervous system is also involved in the control of blood pressure, 
and  is  the  most  rapid  in  responding  to  the  fall  in  pressure  as  it  receives 
information from the baroreceptors which relays to the vasomotor centre.  A fall 
in pressure causes the activation of the sympathetic nervous system, which leads 
to vasoconstriction of arteries and veins (α adrenoreceptors) and an increase in 
contracting of the heart (β adrenoreceptors) (Julius S, 1993). 
The capillary fluid shift mechanism is the exchange of fluid which occurs across 
the capillary membrane between the blood and the interstitial fluid. The fluid 
movement  is  controlled  by  the  capillary  blood  pressure,  the  interstitial  fluid 
pressure and the osmotic pressure of the plasma. Low blood pressure results in 
fluid moving from the interstitial space into the circulation in a bid to restore 
blood volume and blood pressure.  
1.1.2   Mendelian forms of inheritance 
The multifactorial nature of essential hypertension and blood pressure variation 
can  lead  to  complications  in  understanding  how  many  genes  are  involved  in 
having  an effect  on  the  trait  loci,  and  how  they  impart an  influence  on the Wendy Crawford    19 
overall increase in BP.  Mendelian inheritance is also known as a monogenic form 
of inheritance, and molecular genetics has identified rare mutations in 8 genes 
which cause this form of hypertension.  It focuses on rare mutations in single 
genes which lead to a great influence on BP.  The mutated gene products act on 
the same physiologic pathway in the kidney, affecting renal salt absorption.  A 
form  of  aldosteronism  which,  as  yet,  has  not  had  disease  causing  mutations 
identified, is also described (Geller DS et al. 2008).   
1.1.2.1  Glucocorticoid-remediable aldosteronism 
Glucocorticoid remediable aldosteronism (GRA) is an autosomal dominant trait 
which  displays  signs  of  early  onset  hypertension  with  normal  or  elevated 
aldosterone levels despite suppressed plasma rennin activity (Sutherland DJ et 
al. 1996).  Features of this syndrome include variations in hypokalaemia (low 
serum potassium levels) and metabolic acidosis (increased blood pH) (Rich GM et 
al. 1992).  The defining feature of this disease is that exogenous glucocorticoids 
completely suppress endogenous secretion of aldosterone.  Duplication in genes 
caused  by  unequal  crossover  brings  about  GRA.    The  genes  encode  for  rate 
limiting  enzymes  for  aldosterone  biosynthesis  in  the  adrenal  glomerulosa, 
aldosterone  synthase  (CYP11B2),  and  the  enzyme  involved  in  cortisol 
biosynthesis  in  the  adrenal  fasciulata,  steroid  11  β hydroxylase  (CYP11B1).  
CYP11B1’s expression is regulated by adrenocorticotropic hormone (ACTH).  The 
duplication  leads  to  a  chimeric  gene  which  encodes  for  a  protein  with 
aldosterone  synthase  enzymatic  activity.    ACTH  regulates  expression  of  the 
chimeric  gene  in  the  adrenal  fasciulata,  rather  than  the  normal  hormonal 
regulator, ANG II, which leads to aldosterone secretion, and therefore artificially 
high aldosterone synthase activity.  This results in expanded volume of plasma, 
which suppresses renin secretion, but does not reduce aldosterone secretion.  
The  reabsorption  of  Na
+  increases  K
+  and  H
+  secretion,  which  leads  to  the 
development of hypokalaemia and metabolic acidosis. 
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1.1.2.2  Syndrome of apparent mineralocorticoid excess 
Syndrome of apparent mineralocorticoid excess (AME) is an autosomal recessive 
disease  which  displays  symptoms  of  early  onset  hypertension,  coupled  with 
hypokalaemia and metabolic acidosis.  Mutations occur in the HSD11B2 gene, 
which  codes  for  11  β hydroxysteroid  dehydrogenase,  a  kidney  isozyme.    The 
isozyme converts circulating cortisol to cortisone, and as such, the mutation in 
this  gene  leads  to  increased  levels  of  cortisol  in  the  kidney.    Without  the 
protective mechanism of HSD11B2 gene, which acts indirectly on the specific 
mineralocorticoid receptor (MR) for aldosterone, the excess of cortisol activates 
the MR, and leads to hypertension (Funder JW et al. 1988; Stewart PM et al. 
1987). 
1.1.2.3  Mutations in mineralocorticoid receptor      
  – Hypertension exacerbated in pregnancy 
This is an autosomal dominant form of hypertension which has been identified in 
pregnancy (Geller DS et al. 2000).  It is caused by a mis sense mutation in the 
MR,  S810L  in  the  ligand  binding  domain  of  MR  (annotated  as  MR L810).  
Investigation of the patient’s close family shows that carriers of the MR L810 
gene all developed hypertension before the age of 20.  Further investigation of 
this MR mutant receptor indicated partial activation when starved of steroids, 
and  normal  activation  in  the  presence  of  aldosterone.    Steroids  such  as 
progesterone which normally bind, but have no influence on MR, are all strong 
agonists on the mutant MR.  Progesterone levels normally rise by about 100 fold 
during  pregnancy,  and  may  have  an  influence  on  patients  with  MR L810  to 
develop severe hypertension, associated with complete suppression of the renin 
angiotensin system.  Molecular modeling of L810 demonstrated that the binding 
domain in helix 5 forms a new van der waals interaction with the A773 in helix 3, 
which eliminates the need for the hydroxyl group of aldosterone to interact with 
the N770 on helix 3.  This indicates the importance of the role of this interaction 
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1.1.2.4  Liddle syndrome 
Liddle syndrome is an autosomal dominant disease, which is identified by early 
onset  hypertension,  which  is  characterized  by  hypokalaemic  alkalosis, 
suppressed renin activity and lower levels of plasma aldosterone.  The disease is 
caused by a mutation in either the β or γ subunits of ENaC (epithelial sodium 
channel).  This mutation leads to a deletion of the cytoplasmic Carboxyl termini, 
and displays a premature stop codon in the gene (Shimkets RA et al. 1994).  The 
mutation leads to an increase in ENaC activity due to an increased number of 
channels at the cell surface of the distal nephrons (Snyder PM et al. 1995).  This 
larger number of channels is due to a reduction in their clearance, and also a 
longer half life (Shimkets RA et al. 1997).  This leads to a volume expansion, 
low renin form of hypertension.  
1.1.2.5  Mutations  in  peroxisome  proliferator-activated 
  receptor-g g g g       
Peroxisome proliferator activated receptor gamma (PPARγ) is a nuclear hormone 
receptor  which  has  been  identified  as  a  key  regulator  of  adipocyte 
differentiation (Tontonoz P et al. 1994).  Mutations in the gene have been found 
in  conjunction  with  syndromes  of  insulin  resistance,  diabetes  mellitus  and 
hypertension  (Barroso  I  et  al.  1999).    Thiazolidinedione  is  an  anti diabetic 
medication which improves insulin sensitivity, has hypotensive effects on BP and 
also reduces blood sugar levels.  It is thought that this drug binds to PPARγ, and 
indeed,  2  mutations  in  the  ligand  binding  domain  leads  to  severe  insulin 
resistance, diabetes mellitus and hypertension at a very young age (Barroso I et 
al. 1999).   
1.1.2.6  Syndrome of hypertension, hypercholesterolaemia and                           
  hypomagnesaemia 
This syndrome is manifested through mitochondrial inheritance, and is caused by 
a  mis sense  mutation  on  the  mitochondrial  tRNA  (MT TI)  gene.    This  was 
identified through passage of the syndrome through the maternal lineage.  The Wendy Crawford    22 
mutation leads to a cytidine residue in place of the highly conserved uridine 
residue, which impairs ribosome binding (Ashraf SS et al. 1999).    
1.1.2.7  Hypertension with Brachydactyly 
Hypertension with Brachydactyly (HTNB) is a severe autosomal dominant disease 
which is associated with short stature and shortened finger bones.  It develops 
with age, and progresses into severe hypertension.   HTNB is one of the only 
forms  of  mendelian  hypertension  which  closely  resembles  essential 
hypertension.    This  is  due  to  the  responses  to  renin,  aldosterone,  and 
norepinephrine appearing to be normal, and no salt sensitivity (Schuster H et al. 
1996).  Studies on the autonomic nervous system revealed decreased baroreflex 
sensitivity with significantly impaired blood pressure buffering, which suggests 
that  hypertension  in  the  patients  may  be  related  to  an  abnormality  in  the 
baroreceptor reflex function (Jordan J et al. 2000). 
1.1.2.8  Nonglucocorticoid-remediable Aldosteronism 
This is a familial form of GRA as previously described (1.1.2.1), but differs to it 
in  that  it  does  not  respond  to  glucacorticoid  dexamethasone  treatment.  
Patients  may  present  with  symptoms  of  bilateral  adrenal  hyperplasia  or 
unilateral adenoma, and also will develop hypertension in adulthood (Stowasser 
M  et  al.  1992).    Primary  studies  of a  large  kindred have  suggested a  link  to 
chromosome  7p22.    However,  mutations  causing  the  disease  are  yet  to  be 
identified (Jeske Y et al. 2008). 
1.1.2.9  Pseudohypoaldosteronism type II 
Pseudohypoaldosteronism type II (PHA II) is an autosomal dominant disease, also 
known as Gordon’s Syndrome.  Characteristics include familial hypertension with 
hyperkalaemia,  a  slight  increase  in  hypercholaemic  metabolic  acidosis,  and 
thiazide  sensitivity,  but  otherwise,  relatively  normal  renal  function.    WNK 
kinases  (With  No  K  (lysine)) are  the  genes  responsible  for  PHA II.    Mutations 
occur in WNK1 and WNK4, which are normally expressed in the distal nephrons of 
the  kidney  (specifically  the  distal  convoluted  tubules  and  cortical  collecting 
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causes the mutation, and has a cysteine in place of the lysine residue, leading to 
increased WNK1 expression.  Four mis sense mutations cause the change in the 
WNK4 gene, 3 of which are charge changing substitutions, clustered in a span of 
4  amino  acids  (Wilson  FH  et  al.  2001).    The  fourth  mutation  is  also  charge 
changing substitution.  A target for the WNK kinases is the thiazide sensitive   
Na Cl co transporter (NCC), which mediates reabsorption of Na
+ with Cl
  and is 
expressed mainly in the distal convoluted tubule.  The normal WNK4 kinase is a 
negative regulator of the NCC, and PHA II WNK4 mutations negate this inhibitory 
function, and lead to the physiologic effects seen in this form of hypertension.  
However, WNK1 mutations prevent WNK4’s suppression of the NCC (Wilson FH et 
al. 2003). 
1.2 Essential Hypertension 
Essential Hypertension is defined as a rise in blood pressure of unknown cause, 
which can increase the risk of cerebral, cardiac and renal events (Carretero OA 
& Oparil S. 2000).  In industrialised countries, it is the most common form of 
hypertension, affecting more than 95% of hypertensive patients.  This may be 
influenced by both genetic and environmental factors (such as obesity, insulin 
resistance,  high  alcohol  intake,  high  salt  intake  (in  salt sensitive  patients), 
increasing age, lack of exercise, stress, low potassium intake, and low calcium 
intake).  It is a complex polygenic disorder, which affects more than 25% of the 
adult population (Dominiczak AF et al. 2005).  This has a direct impact on the 
health care system, due to the cost of treatments, hospital admissions and care 
required.  A positive diagnosis is usually made when the average of 2 or more 
diastolic blood pressure (BP) readings is ≥90 mm Hg, or when the average of 2 or 
more systolic BP readings is consistently ≥140 mmHg.  Although it is said to be of 
unknown cause, it is usually found in association with other cardiovascular risk 
factors, such as ageing, obesity, diabetes, high alcohol consumption, high salt 
consumption,  stress,  lack  of  exercising  and  hyperlipidaemia,  which  are  all 
factors  which  increase  BP.    Early  events  in  the  course  of  hypertensive 
cardiovascular  disease  include  subtle  target organ  damage,  such  as  left 
ventricular hypertrophy (LVH), microalbuminuria and cognitive dysfunction.  If 
allowed to continue untreated for a long period, events such as stroke, heart 
attack, renal failure and dementia can occur (Messerli FH et al. 2007). Wendy Crawford    24 
Blood pressure (BP) and hypertension show a high degree of genetic heritability 
(Lifton RP. 1996).  The genetic contribution to the development of hypertension 
is  complicated  by  many  factors.   BP  is  phenotypically  determined  by cardiac 
output  and  total  peripheral  resistance,  which  are  in  turn  controlled  by 
intermediary  phenotypes,  such  as  the  autonomic  nervous  system, 
vasodepressor/vasopressor  hormones,  cardiovascular  system  structure,  body 
fluid  volume  and  renal  function.    The  intermediary  phenotypes  add  to  the 
complexity as they are also controlled by a variety of mechanisms, including BP 
(Williams RR et al. 1994).  Family studies, involving biological children, adopted 
children,  identical  and  non identical  twins,  and  siblings  show  that  there  is  a 
higher  correlation  of  BP  between  parents  and  biological  offspring  than  with 
adopted offspring.  Identical twins show a higher correlation in BP than non 
identical twins (Feinleib M et al. 1977).  There is also a higher correlation in BP 
within families than between families (Longini IM et al. 1984).  This suggests 
that there is a familial correlation, which results from a genetic influence on 
blood pressure.  BP is a quantitative trait which is normally distributed in the 
general population, and is a significant determinant of ischemic heart disease, 
cerebrovascular disease, atrial fibrillation, and heart failure (MacMahon S et al. 
1990).    In  the  past  15  years,  many  genomic  locations  contributing  to 
hypertension in rodent models have been mapped (Rapp JP. 2000, Dmitrieva RI 
et al. 2009).   
1.3 Left Ventricular Hypertrophy 
LVH  is  the  thickening  of  the  myocardium  of  the  left  ventricle  of  the  heart.  
Ventricular hypertrophy can occur naturally as a reaction to aerobic exercise and 
strength  training,  but  it  is  most  frequently  a  pathological  reaction  to 
cardiovascular  disease  or  high  blood  pressure.    Although  directly  related  to 
systolic blood pressure, other factors including age, sex, race, body mass index 
and stimulation of the renin angiotensin aldosterone and sympathetic nervous 
systems play an important role in the pathogenesis of LVH.  Understanding of the 
genetic  control  and  molecular  mechanisms  of  LVH  are  relatively  recent 
developments.    It  is  known  that  ANG  II  is  involved  in  the  up regulation  of 
transforming growth factor β1 (TGF β 1) expression and the downregulation of 
the expression of the Wnt transmembrane receptor frizzled 2 (Fzd2) on smooth 
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signal transduction pathways (Berk BC et al 2007; Castoldi G et al 2005).  Gene 
expression of matrix metalloprotease 14 (MMP14) was down regulated in LVH 
tissue.  This may have an impact on blood vessel formation and capillary supply 
in LVH (Ridinger H et al 2009).  Matrix metalloprotease 2 (MMP2) is involved in 
vascular remodelling of hypertrophied hearts, and is co expressed with MMP14 
(Friehs I et al 2006; Seeland U et al 2007).   Ridinger H et al have also shown 
that MMP2 gene expression is down regulated in their disease model.  
LVH itself is not classified as a disease, it is a feature of hypertensive heart 
disease, and can be used as a marker for disease involving the heart (Messerli FH 
et  al.  2007).    LVH  can  reflect  the  hearts’  physiological  adaptation  (or 
physiological remodelling) to the increase in workload of the heart after heavy 
exercise/physical training (Kahan T & Bergfeldt L. 2005).  However, it can also 
develop as an adaptive response to an overload in pressure or volume associated 
with hypertension, which results in the reduction of stress in the cardiac wall 
(Grossman W et al. 1975).  It is also considered to be an important predictor of 
the high incidence of cardiovascular complications, such as myocardial infarction 
(MI), congestive heart failure and cardiovascular mortality (Levy D et al. 1990).  
Following  an  acute  MI,  myocardial  hypertrophy  is  a  part  of  the  pathological 
remodelling process, and is also a common finding in patients with congestive 
heart failure.  Remodelling refers to the change in size, shape or function of the 
heart  after  an  injury  to  the  ventricles.    It  may  also  be  caused  by  chronic 
hypertension and valvular heart disease.  In pathological remodelling, volume 
overload causes ventricular dilation, where new sarcomeres are added in series, 
to existing ones, which increases the overall volume of the ventricle.  This is 
known as eccentric hypertrophy (Vinereanu D  et al. 2002). Pressure overload 
leads to a substantial increase in systolic blood pressure, and the heart responds 
by  adding  new  sarcomeres  in parallel  to  existing  ones,  which  increases  the 
overall wall thickness.  This is known as concentric hypertrophy (Kasikcioglu E et 
al. 2004) (Figure 1.2). Wendy Crawford    26 
 
Figure 1.2 Schematic of the events involved in pathological heart remodelling 
The geometric effects on the cardiac cells following the pathological events leading to 
hypertrophy.    Blood  volume  overload  leads  to  eccentric  hypertrophy.    Blood  pressure 
overload leads to concentric hypertrophy. 
Cardiomyocytes are the major source of remodelling in the heart, however, to a 
lesser extent, the fibroblasts, collagen, interstitium and coronary vessels also 
play a role.  Dilation of the chamber arises from the infarct region.  Initially, the 
remodelling process may be seen as beneficial, as there is improvement in LV 
function and cardiac output.  However, over time the heart shape becomes more 
elliptical,  and  ventricular  mass  and  volume  increase,  which  affects  cardiac 
function.  This may eventually lead to an impairment in the heart’s ability to 
relax between contractions. 
There is also an increased risk for sudden cardiac death in subjects with LVH.  In 
order to understand the development of LVH, the structure of the myocardium, 
which has three morphological compartments, is detailed as follows: 
1) The muscular compartment: consists of myocytes which is the dominant cell 
type in a normal heart.  It comprises 30% of the myocardial cells and is 70% of 
cardiac tissue volume; 
 
2) The interstitial compartment, which is comprised of fibroblasts and collagen; 
 
3) The vascular compartment, with smooth muscle and endothelial cells. 
Remodelling of  the myocardium,  with  an  increase  in  fibrous  tissue  can come 
about following an increase in LV wall stress.  This LV wall stress can stimulate 
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myocyte hypertrophy, collagen formation and fibroblasts.  These changes will 
subsequently reduce LV compliance, which in turn leads to diastolic dysfunction.  
An  increase  in  LV  wall  stress  is  the  principal  mechanical  factor  in  the 
development  of  LV  hypertrophy,  and  blood  pressure  the  most  powerful 
determinant of LV mass (Kahan T. 1998). 
Recent developments in Cardiomyocyte research, involving micro RNA’s have led 
to, amongst others, the identification of miR 208, which is encoded by an intron 
of the α Myosin Heavy Chain (αMHC) gene.  It has been found that this cardiac 
specific  gene  is  necessary  for  cardiomyocyte  hypertrophy,  fibrosis,  and  also 
expression of β Myosin Heavy Chain (βMHC), (which is in response to stress and 
hyperthyroidism)  (Rooji  EV  et al.  2007).      miR 21  has  been  shown  to be  up 
regulated through cardiac remodelling of fibroblasts.  It is thought to regulate 
the ERK MAP kinase signaling pathway in cardiac fibroblasts, which in turn has an 
impact  on  total  cardiac  structure  and  function,  thus  allowing  cardiac 
hypertrophy and fibrosis in response to pressure overload (Thum T et al. 2008).  
However, further work on miR 21 has suggested that it doesn’t have a role in 
cardiac remodelling, as miR 21 null mice have been identified as having similar 
traits of cardiac stress, hypertrophy, fibrosis, up regulation of stress response 
genes,  and  loss  of  cardiac  contractility,  when  compared  to  wild type  mice 
(Patrick DM et al. 2010). 
1.4  Animal Models 
The  use  of  animals  as  experimental  models  has  been  essential  to  human 
understanding of our own diseases.  In cardiovascular disease especially, animal 
models allow us to study the disease in the early stages, the mechanisms of the 
pathogenesis, and also the effects of drug therapies (Doggrell SA. & Brown L. 
1998).  The ideal model should have the following characteristics: 
1) The animal model should mimic the human disease; 
 
2) Should allow studies in a chronic but stable disease; 
 
3) Should produce symptoms which are predictable and controllable; 
 
4) Will easily meet economical, technical and animal welfare considerations; 
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5) Will allow for relevant cardiac, biochemical, molecular and haemodynamic 
measurements to be taken. 
 
The  rat,  mouse  and  human  genomes  encode  for  a  similar  number  of  genes.  
Almost all human genes have orthologues within the rat genome, and roughly 
40%  of  the  rat  genome  has  eutherian  homology  with  the  mouse  and  human 
genome (Rat Genome Sequencing Project Consortium. 2004).  This, along with 
the development of the rat genome sequencing, and developments in software 
for the analysis has allowed for translational studies to occur between humans 
and rats. 
1.4.1   Mouse 
Until  recently,  the  mouse  remained  the  dominant  model  for  mammalian 
genetics, and was the preferred system for genetic manipulation.  90% of the 
mouse and human genome shows conserved regions of synteny, at the nucleotide 
level; about 40% of the human genome can be aligned with the mouse genome 
(Mouse Genome Sequencing Consortium. 2002).   
A surgical method for intervention of pressure overloaded hypertrophy, which is 
widely  used in  the  mouse, is  aortic  banding.    This  is  an  excellent  model  for 
evaluating  how  left  ventricular  hypertrophy  develops  in  response  to 
haemodynamic  stress.    With  the  use  of  this  technique,  a  mouse  model  was 
produced  which  could  be  quickly  and  reproducibly  banded  in  the  transverse 
aorta, but  which also  had  a  low  surgical  morbidity  and  mortality.    Minimally 
invasive transverse aortic banding (MTAB) allowed acute and chronic increase in 
the LV systolic pressure, increased the heart weight to body weight ratio, and 
also induced myocardial fibrosis (Hu P et al. 2003).   
However,  the  mouse  has  several  disadvantages  in  studies  of  cardiovascular 
disease,  due  to  their  small  size  and  increased  heart  rate.    A  few  models  of 
spontaneous hypertension and LVH are in existence, but these have never been 
developed as an inbred model of human hypertension due to the need to be 
stimulated  or  surgically  prepared.    Although  mice  have  been  used  widely  in 
identifying structural and functional genes, these approaches cannot be utilised 
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1.4.2   Rat 
The use of rats in laboratories originated in Asia, and R. Norvegicus was the first 
to be domesticated for such a purpose.  Over 234 inbred strains of R. Norvegicus 
have  been  selectively  bred,  and  to  become  ‘fixed’  for  disease  alleles  for 
particular  strains  or  colonies  (Greenhouse  DD  et  al.  1990).    Because  of  the 
complexities of human essential hypertension, a large number of rats have been 
bred to provide an animal model of the disease (Rapp JP. 2000).  The use of the 
Rat as a model of hypertension allows us to overcome restrictive factors, such as 
cost,  breeding  and  lengthy  generation  time.    This  is  essential,  as  these  are 
factors which are just not feasible or ethical in human studies.  Rats have many 
advantages  over  mice  as  models  of  hypertension,  as  physiologically  they  are 
closer  to  the  human  condition.    Their  larger  size  allows  for  easier  handling, 
performance  of  surgical  procedures,  is  anatomically  more  proportional  in 
substructures of the organs, and taking physiological measurements.  Also, many 
inbred models have been established for research in to other common human 
diseases,  such as  diabetes,  breast cancer and cognitive behaviour.    Selective 
breeding  of  specific  strains  of  known  aetiology  allows  production  of  inbred 
genetically  homogenous  models.    Brother sister  mating  of  20  generations  is 
normally required to acquire a homozygous strain. 
Recombinant  Inbred  (RI)  strains  provide  an  excellent  resource  for  genetic 
mapping, which allows the opportunity to accumulate a large volume of genetic 
and physiological data over a period of time.  RI strains provide us with the 
ability to study genetically identical biological replicates.  This increases trait 
heritability  by  reducing  environmental  variance.    The  SHR  strain  has  been 
crossed  with  the  normotensive  Brown  Norway  (BN)  strain  to  generate  the 
BXH/HXB panel of RI strains. Integrated gene expression profiling and linkage is 
applied, and it is found that these RI strains are a suitable genetic system for 
large scale identification of positional candidates and regulatory pathways for 
previously  mapped  physiological  QTLs.    Comparative  mapping  has  led  to  a 
compiled data set of candidate genes which are suitable for investigating the 
molecular basis of human hypertension (Hubner N et al. 2005). Wendy Crawford    30 
Genetically heterogeneous stocks (HS) applied a strategy which was developed in 
the mouse which allows for the combination of identification and fine mapping 
of QTL’s in a single population in the rat (Mott R et al. 2000; Valdar W et al. 
2006).  This method exploits the recombinants which have accumulated over 
numerous  generations  of  out breeding  in  genetically  HS,  derived  from  inbred 
strains.  In theory, having the HS makes genome wide genetic association studies 
possible,  as  shown  in  the  mouse,  where  843  QTLs  with  an  average  95% 
confidence interval of 2.8 Mb were identified for 97 phenotypes (Valdar W et al. 
2006).  However, for the HS to be suitable in the analysis of complex traits, it 
depends not only on its genetic constitution, but also on the quality and nature 
of the phenotypes that it can deliver (Solberg LC et al. 2006).  The HS phenotype 
must correspond to that found of the standard laboratory strains, to allow for 
the measurement of many phenotypes on one animal, and to reduce the costs of 
genotyping  incurred  in  genome  wide  studies.    Obtaining  multiple  phenotypes 
from  each  animal  may  raise  an  issue  of  interaction  between  phenotypes 
(particularly  for  behavioral  assays)  and  may  limit  the  total  amount  of 
information that can be obtained from this stock. 
Genome wide association studies (GWAS) are the study of all or most of the 
genes  of  different  individuals  within  a  species  to  identify  variation  of  genes 
occurring  within  the  species.    The  identification  of  the  variants,  genes  and 
pathways involved in diseases could lead to potential route to new therapies, 
better  diagnosis  and  improved  prognosis.    It  is  hoped  that  the  findings  from 
GWAS  will  provide  this.    To  date,  studies  have  been  carried  out  in  Human 
populations.  However, The STAR consortium undertook an extensive study on 
the inbred laboratory rat which analysed 167 distinct strains, two recombinant 
inbred  panels,  and  an  F2  intercross.    They  reported  20,328  single  nucleotide 
polymorphisms  (SNP’s),  and  used  the  majority  of  them,  constructed  a  high 
density genetic map, characterizing disease, and also allowing for identification 
of  potential  QTL’s.    DNA  from  the  SHRSPGla  and  WKYGla  was  submitted  for 
analysis, and identified the 5 34Mb region of chromosome 14 as having a high 
density of SNP’s (Saar K et al. 2008).  A major strategy for gene identification 
are genome wide studies, as these can lead to identification of quantitative trait 
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1.4.3   SHRSP 
The spontaneously hypertensive rat (SHR) strain was developed by Okamoto and 
Aoki in 1963 by selective inbreeding from the WKY, and is relevant to stroke 
research  and  used  widely  to  investigate  hypertension,  and  its’  related 
complications, such as LVH, stroke and renal failure (Ginsberg MM and Busto R. 
1989; Yamori Y. 1991). The WKY strain was selectively bred to produce the SHR 
strain.  The SHRSP is a sub strain of SHR which has exceptionally high BP, and is 
found to be more prone to stroke than the other SHR sub strains.  The SHRSP 
strain is derived from the A sub strain of SHR, and has been selectively bred.  
The  B and  C  sub  strains  are  stroke  resistant  (Takaba  H  et  al.  2004).    SHRSP 
displays the onset of spontaneous hypertension between 8 12 weeks of age, and 
is found to be more prevalent in males than in females, with high BP being fully 
established at 12 weeks of age, at approximately 180 mmHg in males and 150 
mmHg in females.  At the same age, WKY rats show a BP reading of 130 mmHg, 
found in both males and females (Davidson AO et al. 1995).  The SHRSP shares 
pathophysiological similarities in hypertensive CVD between SHRSP and humans, 
including LVH and endothelial dysfunction. 
1.5 Identification of Quantitative Trait Loci 
Polygenic inheritance is the inheritance of a phenotypic characteristic which is 
linked to two or more genes and their interaction with the environment. Unlike 
the monogenic traits, polygenic traits do not follow the patterns of Mendelian 
inheritance.    Polygenic  phenotypes  vary  along  a  continuous  gradient.  
Quantitative trait loci (QTL) refers to the stretches of DNA which are closely 
linked to genes which underlie a particular trait, e.g, essential hypertension,  
and may be used to identify the candidate genes underlying the trait.  A genome 
wide linkage study was carried out to map QTL’s, and the genome wide scan of 
an  F2  cross  between  SHRSP  and  WKY,  the  QTL  for  LVMI  was  identified  on 
chromosome 14 (Clark JS et al. 1996).  Other QTL’s of associated interest were 
identified on chromosome 2 and 3 (McBride MW et al. 2003).  Chromosome 2 
QTL’s include systolic and diastolic BP (in both non salt and salt loaded animals), 
which is also seen in the male F2 hybrids only.  Chromosome 3 analysis indicated 
QTL’s for pulse pressure (in both non salt and salt loaded animals) and systolic Wendy Crawford    32 
and diastolic BP (salt loaded animals only).  Radiotelemetry was used to measure 
the phenotype haemodynamic parameters of systolic, diastolic and mean arterial 
pressure, heart rate and motor activity, to confirm the genotype of the strains 
(Davidson AO et al. 1995, Clark JS et al. 1996).  The SHRSP and WKY parental 
strains  were  bred  to  generate  heterozygous  F1  offspring.    The  F1  offspring 
undergo  brother sister  mating  to  give  F2  generation,  which contain  a  random 
genetic  compliment  of  the  parental  strains.    The  F2  generation  was  then 
genotyped,  using  PCR  amplification,  with  polymorphic  microsatellite  markers 
which span the genome.  Phenotypic data is also collected for this generation 
from non salt and salt loaded, in both male and female rats.  This data is then 
merged using computer software (MAPMAKER/EXP 3.0 and MAPMAKER/QTL 1.1), 
and the probability (which is presented as a LOD value) of for each trait is set 
against the genomic positions.  The LOD is a statistical test in linkage analysis 
which compares  the  likelihood  of obtaining  the test  data  if the  two  loci are 
indeed linked, to the likelihood of observing the same data purely by chance. 
Positive LOD score favor the presence of linkage, whereas negative LOD scores 
indicate that linkage is less likely. By convention, a LOD score greater than 3.0 is 
considered evidence for linkage, and a LOD score less than  2.0 is considered 
evidence to exclude linkage (Figure 1.3). Wendy Crawford    33 
 
Figure 1.3 Rat chromosome 14 linkage map and LVMI localisation. 
The genome wide linkage analysis shows the LOD scores in relation to the genotyping 
markers.  Distances between the markers are shown in cM.  The red broken line denotes a 
significant LOD threshold, determined by 10,000 permutations of the data.  LVMI QTL is 
confirmed using simple interval mapping analysis (green line), LVMI QTL analysed using 
composite  interval  mapping  (red  line),  LVMI  QTL  identified  using  multiple  marker 
analysis (blue line).  The QTL for LVMI is located between D14Mgh3 (marked on the 
linkage map) and R58 (not marked on the linkage map) markers, which are approximately 
12.3 cM apart. 
1.5.1   Congenic Strains 
Congenic strains are constructed to confirm the existence of QTLs, and to begin 
narrowing the region for gene identification (Zhang QY et al. 1997).  Congenic 
breeding  was  initiated  to  bring  about  strains  of  animals  which  receive  a 
homologous region containing the QTL of interest, which has been selected from 
a donor animal which displays the quantitative trait.  If the congenic interval 
lacks a gene (or genes), which is imperative to the genotype, then this should 
show a phenotypic difference between the strains.  Reciprocal congenic strains 
have previously been constructed to identify genetic dissection of a BP QTL on 
chromosome  1  (Clemitson  JR  et  al.  2007).  There  are  2  methods  for  the 
production of the congenic strain. The traditional method involves serially back 
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crossing the donor strain with the recipient strain.  With each back cross, the 
offspring are genotyped only in the region of interest until the strain has been 
fixed.    However,  this  may  allow  for  a  crossover  in  other  regions  which  will 
remain  undetected.    The  back crosses  are  performed  between  8 12  times  to 
ensure >99% of the genetic background from the donor strain has been replaced 
by the recipient.  The second method, “Speed congenics” is applied by using a 
marker directed breeding programme in conjunction with genetic linkage maps, 
to achieve the congenic strain in 3 4 generations (Jeffs B et al. 2000).  After the 
fourth backcross generation, <1% of contamination is predicted (Figure 1.4).  The 
polymorphic markers used to screen the region of interest, and also the entire 
background of the genome, and are spaced approximately 25 cM apart.  The 
males  are  genotyped,  and  the  best  males  are  chosen  with  the  least 
heterozygosity in the background to continue the speed congenic breeding. 
 
Figure 1.4 Traditional breeding v Speed congenics 
The change in shading, from grey to white represents the increasing dilution of the donor 
genome in the genetic background. F = first filial generation, B = backcross. 
 
    Speed 
x  x 
Donor 
Donor 
Recipient 
Recipient 
-/- QTL  +/+ QTL  -/- QTL  +/+ QTL 
F1 
B1 
B2 
B3 
B4 
B5 
B6 
B8 
B7 
F1 
 
B2 
B3 
B4 
+/- QTL 
+/- QTL 
+/- QTL 
+/- QTL 
+/- QTL 
+/- QTL 
+/- QTL 
+/- QTL 
+/- QTL 
QTL +/-  
QTL +/-  
QTL +/-  
QTL +/-  
QTL +/-  
Average % 
heterozygous 
(D/R) segments 
100% 
50% 
12.5% 
3.13% 
0.78% 
50% 
75% 
93.7% 
98.4% 
99.6% 
x 
+/- QTL  +/- QTL  -/- QTL 
Fixed 
Congenic 
% 
Recipient 
genome 
  Traditional    Wendy Crawford    35 
1.6 Chromosome 14a 
The chromosome 14a congenic strain has been generated to identify and confirm 
the quantitative trait loci (QTL) for Left Ventricular Mass Index (LVMI), which 
can be regarded as an indicator for LVH, and is a clinically important marker of 
cardiovascular disease (Antoniucci D et al. 1997).  The chromosome 14a congenic 
breeding  strategy  introgressed  segments  of  spontaneously  hypertensive  rat 
stroke prone (SHRSP) strain onto a Wistar Kyoto (WKY) background, to give the 
WKY.SPGla14a strain, and WKY strain onto the SHRSP background to give the 
SP.WKYGla14a  strain  (Figure  1.5).    The  strains  were  confirmed  through 
genotyping. 
 
Figure  1.5  Schematic  of  the  SHRSP,  WKY  and  the  chromosome  14  congenic  strains  using 
microsatellite markers. 
Shows the positioning and size of the congenic region of the chromosome 14a congenic 
strains.    The  genotyping  markers  used  indicate  the  location  of  the  crossover  regions, 
integrating WKY onto SHRSP background to give SP.WKYGla14a strain, and integrating 
SHRSP onto WKY background to give WKY.SPGla14a strain. 
1.6.1   Phenotype data 
A  variety  of  echocardiographic  techniques  were  carried  out  in  parental  and 
congenic  rats  at  5  week  and  16  week  time  points  which  measured  LVMI  and 
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systolic  BP,  and  were  analysed  by  comparing  between  the  parental  strains 
(SHRSP and WKY) and their congenic strain.  Echocardiograph (ECG) is a useful 
method  to  use,  as  it  provides  results  in  a  non invasive  manner,  allowing 
longditudinal studies in the same animal.  LVMI is significantly increased in the 
WKY.SPgla14a at both the 5 and 16 week time point, compared to WKY, and is 
significantly decreased in the SP.WKYgla14a at both  the 5 and 16 week time 
point, compared to SHRSP (Figure 1.6A).  This result confirms the capture of the 
LVMI QTL in both congenic strains. 
The systolic BP measurements were obtained using the radiotelemetry method, 
over a period of weeks. The same rats were used from the strains along the time 
course  of  data  collection,  and  this  allows  the  change  in  BP  readings  to  be 
observed.  The SHRSP and the SP.WKYGla14a strains both display hypertensive 
systolic  measurements.    The  WKY  and  WKY.SPGla14a  strains  both  show 
normotensive systolic measurements.  However, there is a significant difference 
between the strains, which suggests the WKY.SPGla14a strain is showing SHRSP 
qualities in BP control (Figure 1.6B).  This also indicates BP independent cardiac 
hypertrophy events are occurring.   
The  myocardial  performance  index  (MPI)  was  used  to  assess  LV  function.    It 
relies on the pulse wave Doppler measurements taken throughout specific parts 
of systole and diastole of the beating process.  Consecutive beats are measured 
and then averaged to assess each parameter.  The timed intervals are measured 
from the mitral inflow and LV outflow velocity time intervals.  Isovolumetric 
relaxation time (IVRT) is classified as the interval between mitral valve closing 
and  opening.    Isovolumetric  contraction  time  (IVCT)  is  classified  as  the  time 
during early systole when the ventricles contract, with no corresponding change 
in  volume.    MPI  is  significantly  reduced  in  the  WKY  when  compared  with 
WKY.SPgla14a at both 5 and 16 week time points.  MPI is significantly reduced in 
the SP.WKYgla14a when compared with SHRSP at both 5 and 16 week time points 
(Figure 1.6C & D).  This result confirms that there is correlation between LV 
function in the strains, and the confirmation of the LVMI QTL.  This is important 
as  it  justifies  the  effort  to  identify  the  genes  underlying  LVMI  through  the 
construction of the congenic strains. 
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Figure  1.6  Graph  showing  the  ECG  measurements  in  SHRSP,  WKY,  SP.WKYGla14a  and 
WKY.SPGla14a at 5 and 16 weeks of age. 
The graph shows significant difference in the LVMI (mg/g), when comparing the SHRSP 
with  the  SP.WKYGla14a  congenic  strain,  and  the  WKY  with  the  WKY.SPGla14a 
congenic  strain  at  both  time  points  (Figure  1.6A).    The  line  graph  shows  the  BP 
measurements, taken over a time period (Figure 1.6B).  The picture shows MPI output, as 
measured using the Doppler pulse wave method, by IVCT, IVRT and ET (Figure 1.6C).  
The  graph  shows  statistical  difference  in  MPI,  when  comparing  the  SHRSP  with  the 
SP.WKYGla14a congenic strain, and when comparing the WKY with the WKY.SPGla14a 
congenic strain at both time points (Figure 1.6 D). 
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Objectives 
 
Previous  work  involved  the  generation  of  chromosome  14  congenic  strains  in 
both  the  SHRSP  and  WKY  genetic  backgrounds  confirming  the  QTL  for  left 
ventricular mass index in the SHRSP.  Using a combination of congenic strains 
and microarray gene expression profiling the aim of this work was to identify and 
validate positional candidate genes within the transferred congenic interval. 
Aims 
·  To use Affymetrix exon array to identify differentially expressed genes in 
hearts isolated from 5 week old SHRSP, SP.WKYGla14a, WKY.SPGla14 and 
WKY  animals.    The  analysis  will  focus  specifically  on  the  minimally 
transferred congenic interval (29Mbp). 
·  To  extend  this  analysis  in  all  four  strains  using  Illumina  genome wide 
expression profiling in neonatal, 5 week and 16 week old animals. This 
analysis  will  prioritise  the  neonatal  time  point  prior  to  the  onset  of 
hypertension and cardiac hypertrophy in the SHRSP.   
·  To  validate  selected  positional  candidate  genes  and  identify  putative 
causative SNP’s in the regulatory and coding regions of the target genes. 
·  To  investigate  the  functional  role  of  cardiomyocytes  and  fibroblasts  in 
hypertrophy and fibrosis in the WKY and WKY.SPGla14a strains. 
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2.1 General Laboratory Practice 
This chapter outlines general laboratory practises and laboratory methods that 
are common to more than one chapter.  Laboratory equipment and reagents 
were of the highest commercially available grades.  A laboratory coat and latex 
or non latex powder free gloves were worn during all procedures.  Hazardous 
reagents were handled appropriately as described in the Control of Substances 
Hazardous to Health regulations, using laboratory spectacles or facemask and/or 
a fume hood where appropriate. 
Laboratory glassware was cleaned in Decon 75 detergent, rinsed with distilled 
water and dried in a 37°C cabinet.  Otherwise, sterile disposable plastic ware 
was used, including 0.5 ml, 1.5 ml and 2 ml microcentrifuge tubes (Greiner Bio 
one) 15 ml and 50 ml Corning centrifuge tubes and 5 ml and 20 ml 'Universal' 
containers (Sterilin).  Reagents were weighed using an Ohaus Portable Advanced 
balance (sensitive to 0.01 g), or a Mettler HK160 balance (sensitive to 0.0001 g).  
Solutions were pH'd using a Mettler Toledo digital pH meter calibrated with pH 
4.0,  7.0  and  10.0  standards  (Sigma).    Volumes  from  0.1   l  to  1,000   l  were 
dispensed with Gilson Medical Instruments pipettes.  Volumes from 1 ml to 25 ml 
were measured with sterile disposable pipettes (Corning) and a Gilson battery 
powered pippetting aid.  Autoclaved distilled water was used to prepare aqueous 
solutions unless stated otherwise, a Jenway 1000 hotplate/stirrer was used to 
aid dissolving and mixing.  Vortexing was carried out using an FSA Laboratory 
Supplies WhirliMixer.  Centrifugation for samples up to 2 ml was performed at 4 
20°C in an Eppendorf 4515 microcentrifuge, larger samples were centrifuged in a 
Sigma 4K15, compatible with 15 ml and 50 ml centrifuge tubes, 20 ml 'Universal' 
tubes and with carriers for standard reaction plates.  Laboratory ware or liquids 
requiring sterilisation were autoclaved in a Priorclave Tactrol 2. A Julabo TW8 
water bath was used for experiments requiring incubations from 37°C to 90°C, a 
Grant SBB14 boiling water bath was used for temperatures up to 100°C. 
Certified  Nuclease free  reagents  and  plastic  ware  was  used  for  experiments 
involving  RNA,  including  Ambion  RNase free  microcentrifuge  tubes,  RAININ 
nuclease free filtered pipette tips and Ambion nuclease free H2O. Pipettes and 
benches were wiped with Ambion RNaseZap reagent before all RNA experiments.   Wendy Crawford    41 
2.2  General Techniques 
2.2.1   Nucleic Acid Extraction 
Genomic DNA was extracted using the Nucleon
® Genomic DNA Extraction Kit (SL 
8508).  250 mg of tissue was weighed and homogenized in 2.5 ml of Reagent A 
with a Polytron 2100 rotor homogeniser at 30,000rpm.  The homogenate was 
centrifuged at 1300g for 10 minutes at room temperature.  The supernatant was 
aspirated, and the pellet was re suspended in 1.5 ml of Reagent B.  150 l of 
sodium  perchlorate  70%  (v/v)  was  added,  and  the  suspension  was  inverted  7 
times.  500 l of chloroform was added, and the suspension was inverted 7 times.  
150 l of Nucleon resin was added, and the suspension was placed on a rotary 
mixer for 5 minutes, and centrifuged at 350g for 1 minute at room temperature.  
The upper phase was transferred to a clean microcentrifuge tube, and 2 volumes 
of  cold  EtOH  100%  was  added,  and  inverted  to  precipitate  the  DNA.    The 
precipitate/EtOH mix was then centrifuged at 13,200rpm for 5 minutes at room 
temperature, and the supernatant discarded.  1 ml of cold EtOH 70% (v/v) was 
added, and inverted several times to wash the pellet, and then centrifuged at 
13,200rpm for 5 minutes at room temperature.  The supernatant was discarded 
and the pellet allowed to air dry for 10 minutes at room temperature.  100 l of 
distilled water was added, and the DNA was allowed to re suspend overnight.  
The DNA was then vortexed until the pellet broke down. 
Qiagen  column  and  filter based  miRNeasy  kit  (217004)  was  used  for  RNA 
extraction.  Whole  tissues  or  cells  were  homogenised  in  Qiazol  (700 l/50  mg 
Tissue or 1x10
7 cells).  Cultured cells were rinsed with PBS and homogenised by 
scraping with an RNase free pipette tip, and pipetted up and down to allow 
Qiazol digestion of the cells.  Tissues were homogenised with a Polytron 2100 
rotor homogeniser at 30,000rpm.  The homogenized tissue and cells lysates were 
divided into 700 l aliquots, and the excess may be stored at  80°C for up to 6 
months.  The homogenate was placed at room temperature for 5 minutes, and 
following  that,  140 l  of  chloroform  was  added  and  shaken  vigorously  for  15 
seconds.  The homogenate was placed at room temperature for 5 minutes, then 
centrifuged for 15 minutes at 12,000g at 4°C.  The upper phase was transferred 
to a clean 1.5 ml RNase free tube, and 1.5 volumes of EtOH 100% (Sigma 200 
proof) was added and mixed thoroughly by pipetting up and down.  700 l of the Wendy Crawford    42 
sample was applied to an RNeasy mini spin column placed in a 2 ml collection 
tube, and centrifuged at 8000g for 15 seconds at room temperature.  The flow 
through was discarded.  700 l of Buffer RWT (supplied with the kit, and adjusted 
to volume with EtOH 100% (Sigma 200 proof)) was applied to wash the column, 
and was centrifuged at 8000g for 15 seconds at room temperature.  The flow 
through was discarded.  500 l of Buffer RPE (supplied with the kit, and adjusted 
to volume with 100% EtOH (Sigma 200 proof)) was applied to wash the column, 
and was centrifuged at 8000g for 15 seconds at room temperature.  The flow 
through was discarded.  500 l of Buffer RPE (supplied with the kit, and adjusted 
to volume with EtOH 100% (Sigma 200 proof)) was applied to wash the column, 
and was centrifuged at 8000g for 2 minutes at room temperature.  The flow 
through was discarded.  The RNeasy mini spin column was placed in a fresh 2 ml 
collection  tube,  and centrifuged  at  13,200rpm  for  1  minute  to  eliminate  the 
possibility of carryover of Buffer RPE.  The RNeasy mini spin column was placed 
in a fresh 1.5 ml collection tube, 40 l of RNase free water was applied directly 
to the column and centrifuged at 8000g for 1 minute at room temperature.  For 
tissue lysates, the 40 l of elute was re applied to the column and centrifuged at 
8000g for 1 minute at room temperature.  For tissue lysates with an expected 
higher yield of RNA, a further 40 l of RNase free water was applied directly to 
the column and centrifuged at 8000g for 1 minute at room temperature. 
The TURBO DNA free protocol (AM1907) was carried out on RNA derived from 
tissues,  to  remove  contaminating  DNA  from  RNA  preparations,  and  to 
subsequently remove DNase from the samples.  TURBO DNase has a high affinity 
for DNA and is effective at removing trace amounts of this contaminant.  Routine 
DNase treatment of samples containing <200 l, 4 l of TURBO DNase buffer and 
1 l TURBO DNase was added to 44 l of RNA in an RNase free microcentrifuge 
tube, and incubated at 37°C for 30 minutes.  5 l of DNase Inactivation reagent 
was added, and the mixture was flicked for 2 minutes, and then centrifuged at 
10,000g for 1.5 minutes at room temperature.  The supernatant containing the 
TURBO DNase free RNA was transferred to a clean RNase free microcentrifuge 
tube. 
The RNase Free DNase set (Qiagen 79254) on column DNase digestion was carried 
out on RNA derived from cells.  This protocol was undertaken during the RNA 
extraction protocol as an insert to it.  At the stage of adding 700 l buffer RWT, Wendy Crawford    43 
the protocol diverted to the digestion ptotocol, and continued as follows.  350 l 
buffer RWT was applied to wash the column, and was centrifuged at 8000g for 
15 seconds at room temperature.  10  l DNase I stock solution was added to 70 l 
Buffer  RDD,  mixed  gently  by  inverting  and  applied  to  the  RNeasy  mini  spin 
column.  The RNeasy mini spin column was incubated for 15 minutes at room 
temperature.    350 l  buffer  RWT  was  applied  to  wash  the  column,  and  was 
centrifuged at 8000g for 15 seconds at room temperature.  The miRNeasy kit 
RNA extraction protocol was then re joined at the point of the first application 
of 500 l of Buffer RPE. 
2.2.2   Measuring Nucleic Acid Concentration 
DNA  and  RNA  concentrations  were  measured  using  a  Nanodrop  ND 1000,  a 
spectrophotometer that is sensitive from 2 37000 ng/ l double stranded DNA. 
Absorbance  at  260nm  were  used  for  quantification  of  nucleic  acids,  optical 
density of 1 corresponding to 50ng/ l DNA and 40ng/ l RNA.  Absorbance ratios 
(260 nm/280 nm) of approximately 1.8 for DNA and 2.0 for RNA indicated that 
the nucleic acid preparations were sufficiently free from protein contamination 
for downstream experiments.  Averages of duplicate or triplicate readings were 
taken for samples requiring very precise quantification.  
2.2.3   Polymerase Chain Reaction 
All thermal cycling for standard PCRs was performed on an MJ Research PTC 
Gradient Cycler in 96 well plates (ABgene).  PCR primers were designed using 
the online design tool Primer3 (Rozen et al. 2000)  and purchased from MWG 
Biotech.  
The Taq DNA polymerases used in the above PCR systems have fast processivity, 
but  lack  a  proofreading  capability,  they  are  suitable  for  a  majority  of  PCR 
applications but incorporate incorrect nucleotides approximately every 10,000 
nucleotides.  For  applications  where  absolute  fidelity  of  DNA  replication  was 
required, for example for cloning promoter or cDNA sequences, 'Kod Hot Start' 
DNA  polymerase  (Novagen)  was  used.    Kod  DNA  polymerase  is  derived  from 
Thermococcus  kodakaraensis  thermophilic  bacteria  and  possesses  3' 5' 
exonuclease activity that excises mis incorporated bases during PCR. Kod PCRs Wendy Crawford    44 
were performed according to the manufacturers instructions, reaction mixtures 
and temperature cycling parameters were as follows: 
Reaction mix      Heat Cycling 
        Vol. ( l)   
10x PCR buffer    2.5    94°C  2 min 
dNTPs (1mM)     2.5    94°C  15 sec 
MgSO4 (25mM)    1.0    58 62°C  30 sec 
Fwd primer (5pmol/ l)  1.5    68°C  2.5 min 
Rvs primer (5pmol/ l)  1.5    68°C  10 min 
DNA        1.0 5.0     
Kod (1U/ l)      0.5 
H2O         Up to 25ul 
2.2.4   Agarose Gel Electrophoresis 
Unless  otherwise  stated  1%  (w/v)  agarose  (Eurogentec)  gels  were  used 
throughout, dissolved and electrophoresed in 1 X Tris Borate EDTA (TBE) buffer 
(Fisher Bioreagents).  Gels were electrophoresed at 6 V per cm of gel. BIO RAD 
Power  Pac  300  and  BIO RAD  electrophoresis  tanks  were  used,  1  ng  /  100ml 
ethidium  bromide  (Sigma)  was  added  to  molten  agarose  before  pouring  gels, 
unless stated otherwise.  Gels were visualised by UV transillumination on a BIO 
RAD  Fluor S  MultiImager.    Promega  100bp  or  1kb  DNA  ladders  were  used  for 
sizing products. Samples were loaded with 6 X loading dye (50% glycerol, 0.05% 
bromophenol blue). 
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2.3 Tissue Culture 
Primary  Cardiomyocyte  and  Fibroblast  cells  were  handled  under  sterile 
conditions using class II biological safety cabinets (Holten Safe 2010). Cabinets 
were cleaned before and after use with distilled water and 70% (v/v) ethanol.  
Waste plastics and fluid were decontaminated by steeping for 24hr in 10% (v/v) 
bleach,  plastics  were  then  incinerated  and  fluids  were  poured  into  domestic 
waste drains.  Cells were maintained in 75 cm
2 tissue culture flasks with vented 
caps  (Corning)  in  inCusafe  37°C,  5%  carbon  dioxide  (CO2)  incubators.    Tissue 
culture  experiments  involving  primary  cells  were  performed  in  a  dedicated 
biological safety cabinet and maintained in separate incubators.  
2.3.1   Cell Passage and Cryostorage 
Cells  were  passaged  regularly  to  prevent  overcrowding  in  culture  flasks, 
experiments were performed with cells of lowest possible passage number and 
experiments  were  completed  in  as  few  passages  as  possible.    Unless  stated 
otherwise, passaging was performed by removing culture media and rinsing cells 
gently twice with 7ml sterile PBS (Lonza) before detaching them from the flask 
with 2 10 minutes incubation at 37°C with 2ml 1X TE (0.05% trypsin (w/v); 0.2% 
(w/v) ethylenediamine tetraacetic acid (EDTA)).  Cells were washed with 5 ml 
foetal  calf serum  (FCS) containing  medium,  which  inactivates  the  trypsin, 
aspirated into a 20ml ‘Universal’ container, and centrifuged at 1500 rpm for 5 
minutes. Media/TE was poured off and the cell pellets were re suspended in cell 
media, fresh 75 cm
2 flasks with 13ml media were seeded with 1/3 of the cells 
from the previous passage. 
For  cyrostorage,  cells  from  3  x  75  cm
2  flasks  were  re suspended  in  6ml 
media/10% (v/v) dimethylsulphoxide (DMSO) and divide into aliquots into 4 x 2 
ml  cryovials.  The  cryovials  were  placed  in  an  isopropanol  freezing  container 
(Nalgene) in a  80°C freezer overnight, ensuring freezing no faster than 1°C per 
minute.    The  next  day  cells  were  transferred  for  long term  storage  in  liquid 
nitrogen.  When recovering cells from liquid nitrogen they were thawed to room 
temperature and pipetted into 13ml media in a fresh 75 cm
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was changed the next day, cells were not used for experiments until at least two 
passages and a week out of liquid nitrogen. 
2.3.2   Cell Counting 
In order to accurately seed cell culture flasks and plates with a known number of 
cells,  cells  were  counted  with  a  haemocytometer  (Hausser  Scientific).  
Approximately 10 l of a cell suspension was pipetted under a cover slip onto the 
grid, the number of cells in each 1 mm square was recorded by counting the 
cells in each 0.25 mm  squares, cell crossing the bottom or right hand edge of 
any square were not counted.  The average number of cells in each 1 mm square 
was derived, was multiplied by 10
4 to give the number of cells per ml in the 
suspension.  Dilutions of the cell suspension were made in media to seed the 
correct number of cells per flask or well. 
2.4 DNA Sequencing 
Unless  otherwise  stated,  DNA  sequencing  was  performed  by  purifying  PCR 
products  to  remove  un incorporated  dNTPs,  primers  and  salts,  followed  by 
dideoxy sequencing reactions, and a second purification step before capillary 
electrophoresis to separate sequencing products by size.  Each step is outlined 
below. 
2.4.1   PCR Clean-up 
PCR products were retained in PCR reaction plates and purified for sequencing 
using the Agencourt AMPure kit.  This relies on binding of DNA products over 
100bp in length to paramagnetic beads in the kit solution (i.e. they are attracted 
to  magnets  but  do  not  exhibit  magnetism  themselves).    36 l  of  AMPure  was 
added  to  each  20 l  PCR  reaction,  the  plates  were  briefly  vortexed  and 
centrifuged to 1000 rpm for 1 second to collect the liquid to the bottom of the 
wells.  They were left to stand for 5 minutes and then placed onto a SPRI Plate 
(solid phase reversible immobilisation plate) magnetic plate holder (Agencourt) 
for 10 minutes.  The SPRI Plate has an individual ring magnet for each well in a 
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plate. Keeping the PCR plate on the SPRIPlate, the PCR reaction constituents 
were removed by inverting the plates and shaking forcefully upside down.  The 
beads were then washed with 200 l of freshly prepared 70% (v/v) ethanol for 30 
seconds before shaking forcefully upside down and centrifuging upside down to 
600rpm for 1 second to remove as much ethanol as possible.  PCR Plates were 
removed  from  the  SPRI  Plate  and  left  to  air dry  for  20  minutes  before  the 
addition of 40 l H2O per well.  The PCR plates were vortexed to re suspend the 
AMPure beads, then returned to SPRI Plates plates, 8 l was carefully pipetted 
out per sequencing reaction. If a PCR product was to be sequenced more than 3 
times, multiple 20 l PCRs were performed. 
2.4.2   Dideoxy Sequencing 
Applied Biosystems BigDye Terminator n3.1 Cycle Sequencing kits were used all 
for sequencing reactions in this project, reactions were performed in 96 well 
plates.  Unless  stated  otherwise  all  sequencing  reactions  included  3.5 l  5X 
sequencing buffer; 0.5 l Ready Reaction; 8 l template (purified PCR product); 
3.2 l primer (1pmol/ l); 4.8 l H2O. The temperature cycling program was: 
1) 96°C  45 sec 
2) 50°C  25 sec 
3) 60°C  4 min  
Repeat steps 1) 2) x25 
2.4.3   Sequencing Reaction Purification 
Sequencing  reactions  were  purified  to  remove  reaction  constituents  and 
unincorporated nucleotides and primers prior to electrophoresis using Agencourt 
CleanSEQ  reagent.    10 l  of  CleanSEQ  reagent  was  added  to  each  sequencing 
reaction, followed by 62 l of freshly prepared 85% (v/v) ethanol.  Plates were 
briefly vortexed and centrifuged to 1000 rpm for 1 second to collect the liquid to 
the bottom of the wells, then placed on an SPRIPlate for 3 minutes.  Wells were 
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washed twice with 100  l 85% (v/v) ethanol for 30 seconds each, emptying the 
wells  between  washes.  Wells  were  then  emptied  as  much  as  possible  by 
centrifugation  of  inverted  plates  to  600  rpm  for  one  second.    Plates  were 
removed from the SPRIPlates and air dried for 20 minutes, 40  l of H2O was 
added to each well and CleanSEQ beads were resuspended by vortexing.  Plates 
were briefly centrifuged to 1000 rpm for 1 second and returned to SPRIPlates.  
20  l of sequencing products were loaded into optically clear barcoded 96 well 
plates.    H2O  was  added  to  unused  wells  to  prevent  drying  of  capillaries  and 
plates were covered with Applied Biosystems Septa Seals, which prevented the 
evaporation of products but also allowed the capillaries to enter wells. 
2.4.4   Capillary Electrophoresis 
Sequencing  capillary  electrophoresis  was  performed  on  a  48 capillary  Applied 
Biosystems 3730 Genetic Analyser with 36 cm capillaries.  Electrophoresis was 
preceded by filling the capillaries with fresh POP 7 polymer (Applied Biosystems) 
and warming the capillaries to 60°C.  Sequencing products were separated by 
size by electrophoresis at 8500 volts for 50 minutes. 
2.4.5   Sequencing Analysis 
Sequencing was analysed using Applied Biosystems SeqScape software version 2.1 
Experimental  sequences  were  aligned  with  known  sequences  derived  from 
bioinformatic databases such as UCSC or ENSEMBL genome browsers or product 
information such as plasmid sequences. 
2.5 DNA Cloning 
Eukaryotic expression  vectors  were  employed  in this  project in  the promoter 
region studies, for the generation of recombinant DNA products of expression 
cassettes for future studies from blunt ended PCR products generated using KOD 
polymerase.   
The StrataClone blunt PCR cloning technology uses the combined activities of 
topoisomerase I, from Vaccinia virus and Cre recombinase, from bacteriophage 
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rejoining  DNA  strands,  then  cleaving  the  phosphodiester  backbone  of  a  DNA 
strand  after  the  sequence  5´ CCCTT,  which  forms  a  covalent  DNA–enzyme 
intermediate which conserves bond energy to be used for re ligating the cleaved 
DNA  back  to  the  original  strand.    The  Cre  recombinase  enzyme  catalyzes 
recombination between two loxP recognition sequences.  The StrataClone blunt 
PCR  cloning  vector  mix  contains  two  blunt ended  DNA  arms, of  which one is 
charged  with  topoisomerase  I,  and  the  other  contains  a  loxP  recognition 
sequence on the other end.  Blunt ended PCR products produced by proofreading 
KOD polymerase are then ligated into the vector arms.  The linear molecule 
(vector armori–PCR product–vector armamp/kan) is transformed into a competent cell 
line which expresses Cre recombinase, which allows recombination between the 
vector  loxP  sites,  creating  a  circular  DNA  molecule  (pSC B amp/kan)  which 
replicates in cells growing on media containing ampicillin or kanamycin.  The 
pSC B amp/kan  vector  product  includes  a  lacZ  α complementation  cassette 
which allows for blue white colony screening. 
2.5.1   Transformation of Competent Bacteria 
StrataClone SoloPack Competent Cells provided with the StrataClone Blunt PCR 
Cloning  Kit  (#240207)  were  used  as  hosts  for  eukaryotic  expression  vectors 
throughout this project. The PCR product was first ligated into the vector.  The 
cloning mixture of 3  l of StrataClone Blunt Cloning Buffer, 2  l of PCR product 
(diluted 1:10) and 1  l StrataClone Blunt Vector Mix amp/kan was combined, 
mixed by gentle pipetting, and incubated at room temperature for 5 minutes, 
then  placed  on  ice.    For  transformation,  one  tube  of  competent  cells  per 
reaction  was  thawed  on  ice.    1   l  of  the  cloning  mixture  was  added  to  the 
thawed competent cells, and mixed gently, and incubated on ice for 20 minutes, 
then 'heat shocked' at 42°C for 45 seconds before returning to ice for a further 2 
mintues. 250  l of pre warmed SOC medium (Sigma) was added to the cells and 
they were placed in a shaking incubator (New Brunswick Scientific Inova 44) at 
37°C,  180  oscillations  per  minute,  for  one  hour.  Unless  otherwise  stated  all 
plasmids  used  in  this  project  encoded  ampicillin  resistance  for  selection  of 
transformed  cells.  90  mm  culture  plates  (Sterilin)  of  Luria  agar  (Sigma) 
containing 100  g/ml ampicillin (Sigma) were spread with 40  l of 2% (w/v) X gal 
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the  transformation  mixture  were  spread  onto  each  of  the  Luria  –amp/X gal 
plates.  Culture plates were inverted and placed in a 37°C incubator (Heraeus) 
overnight.  Plates were checked for bacterial colonies the next morning, and 
white colonies were selected to be streaked on a Luria agar plate containing 100 
 g/ml ampicillin, to allow for DNA expansion.  The DNA from the colonies was 
then screened for positive clones through PCR.  Primers specific to the vector 
were designed and used to amplify the insert region.  These PCR products can 
then be sequenced as described in (2.4) 
2.5.2   Glycerol Stocks 
Successfully  transformed  bacteria  were  preserved  for  long term  storage  by 
preparing  glycerol  stocks.  500ul  of  overnight  broth  cultures  was  mixed  with 
500ul sterile autoclaved glycerol, to give 50% (v/v) concentrations and frozen at 
 80°C.  Bacteria  were  recovered  from  glycerol  stocks  by  streaking  for  single 
colonies on selective agar.  
2.5.3   Plasmid DNA Purification 
Plasmid DNA was extracted from bacteria using the filter column based Qiagen 
Plasmid Midi kit.  Bacterial cultures were streaked and grown overnight at 37°C 
on  ampicillin  Luria  agar  plates.    Single  colonies  were  picked  and  used  to 
innoculate a 'starter' culture grown throughout the next day in 5 ml Luria broth 
(Sigma), containing 100  g/ml ampicillin, in a shaking incubator at 37°C.  50  l 
of this culture was used to inoculate 25 ml 100  g/ml ampicillin Luria broth to 
produce an overnight culture from which the plasmid was extracted (25 ml was 
sufficient  for  most  plasmids,  however  when  low  yields  were  obtained,  the 
extraction  was  repeated  with  100  ml  culture).    Bacteria  were  harvested  by 
centrifugation at 6,000 g for 15 minutes at 4°C in a Beckman Coulter Avanti J 
26XP.  Culture media was poured off and the bacteria were re suspended in 4 ml 
buffer P1 (50mM 2 amino 2 hydroxymethyl 1,3 propanediol, pH8; 10 mM EDTA, 
100  g/ml RNase A).  4 ml buffer P2 (200 mM NaOH; 1% sodium dodecyl sulphate 
(SDS)) was added and the solutions were kept on ice for five minutes.  4 ml 
chilled buffer P3 (3 M potassium acetate at pH5.5) was added to neutralise the 
lysate.    The  precipitated  lysates  were  centrifuged  at  20,000g  at  4°C  for  30 Wendy Crawford    51 
minutes, the supernatant was retained and centrifuged again at the same speed 
for a further 15 minutes.  Columns were pre wetted with 4 ml buffer QBT (750 
mM  NaCl;  50  mM  3 morpholinopropanesulfonic  acid  pH7  (MOPS);  15%  (v/v) 
isopropanol; 0.15% (v/v) Triton X 100).  The supernatant was applied and the 
columns were allowed to empty by gravity flow, the columns were washed twice 
with 10 ml buffer QC (1 M NaCl; 50 mM MOPS pH7; 15% (v/v) isopropanol), and 
the plasmid DNA was eluted with 5 ml buffer QF (1.25 M NaCl; 50 mM Tris pH8.5; 
15%  (v/v)  isopropanol)  into  polypropylene  centrifuge  tubes.  Plasmid  DNA  was 
precipitated with 3.5 ml isopropanol and centrifuged at 15,000g for 30 minutes 
at  4°C.  The  supernatant  was  carefully  poured  off,  and  the  pellets  were 
resuspended in 2 ml 70% (v/v) ethanol and divided into aliquots into two 1.5 ml 
microfuge tubes. They were centrifuged at 16,200g for 10 minutes at 4°C. The 
ethanol was carefully pipetted off and the pellets were thoroughly air dried (10 
20 minutes) before re suspending the DNA in 20  l H2O per tube and pooling the 
contents of the two tubes. Total plasmid yields were typically 50 90% of the 
maximum yield quoted for the maxi columns (500  g). 
2.5.4   Agarose Gel DNA Extraction 
Unless stated otherwise agarose gel extraction of PCR products was performed 
with  the  Qiagen  QIAquick  Gel  Extraction  kit  following  the  manufacturer's 
instructions, using a bench microcentrifuge at 10,000g. Bands in agarose gels 
were  visualised  on  a  UV  transiluminator  (UVP)  and  carefully  excised  with  a 
scalpel blade. The bands were weighed and 300  l of buffer QG was added per 
100  g of agarose before heating the agarose/buffer QG mixture to 50°C for 10 
minutes.  After  centrifugation  to  adsorb  the  DNA  to  the  membrane,  the 
membrane was washed with centrifugations with 500  l of buffer QG followed by 
750  l buffer PE (which contains 70% (v/v) ethanol).  All traces of ethanol were 
removed by a final centrifugation for 1 minute.  DNA was eluted in nuclease free 
water. 
2.6 Quantitative Real-Time PCR 
An Applied Biosystems 7900HT Sequence Detection System (Taqman) was used 
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heating block for thermal cycling and detectors to measure fluorescence in each 
well of a 96 well or 384 well optical plate. Fluorescence is measured after every 
amplification  cycle  to  quantify  the  accumulation  of  PCR  product;  during  the 
exponential  phase  of  PCR  cycling  the  rate  of  product  accumulation  is 
proportional  to  template  concentration,  relative  template  abundance  can 
therefore  be  quantified  by  monitoring  increasing  fluorescence  in  each  well 
during temperature cycling. This is explained in more detail below along with 
the specific protocols for cDNA template preparation of and reaction set up. 
2.6.1   Preparation of cDNA 
cDNA  preparations  for  quantitative  real time  PCR  (qRT PCR)  were  made  by 
reverse transcription from RNA templates.  Applied Biosystems 'TaqMan Reverse 
Transcription Reagents' were used for cDNA synthesis using random hexamer or 
oligo dT primers. 1  g of RNA template was used unless RNA concentrations were 
too low; the same amount of RNA template was always used in all reactions in 
the  same  experiment,  dictated  by  the  lowest  RNA  concentration.    Reverse 
transcription reactions were performed in 96 well plates to allow multichannel 
pipettes  to  be  used  for  PCR  reaction  set  up,  the  reaction  constituents  and 
temperature programs used for each kit were: 
Applied Biosystems TaqMan Reverse Transcription Reagents: 
      Vol. 
RNA      Up to 1 g 
H2O      Adjust to 7.7 l 
Then add the following to each tube from a master mix: 
        Vol.( l) 
10X Reaction Buffer    2.0 
MgCl2 (25mM)    4.4 Wendy Crawford    53 
dNTPs (2.5mM ea.)    4.0 
Primers (50 M)    1.0 
RNase Inhibitor (20U/ l)  0.4 
MultiScribe RT (50U/ l)  0.5 
Heat to 25°C for 10 minutes, 48°C for 30 minutes then 95°C for 5 minutes. 
2.6.2   Real-Time PCR 
Applied Biosystems Gene Expression Assays and Custom Gene Expression Assays 
were  used  for  all  qRT PCRs  in  this  project.    The  assays  consisted  of  a  20  X 
reaction mix containing template specific forward and reverse primers (18 mM 
each) and a probe that anneals between the two primers (5 mM).  The probe 
DNA is fluorescently tagged at its 3' end, but fluorescence from intact probes is 
prevented  by  a  quencher  molecule  that  is  bound  to  its  5'  end.    During  PCR 
amplification, the 5' 3' nucleolytic activity of the DNA polymerase cleaves the 
quencher from the probe, resulting in fluorescence levels proportional to the 
amount of PCR product present.  All Gene Expression Assays used in this project 
were  designed  to  anneal  across  two  exons  in  cDNA,  guaranteeing  that  non 
specific amplification did not occur from residual genomic DNA. 
Every effort was made to ensure that the amount of template cDNA was the 
same in each reaction of an experiment, however, given the sensitivity of qRT 
PCR, expression of the gene of interest was always  measured relative to the 
GapDH  housekeeping  control  gene.  The  gene  of  interest  and  GapDH  were 
amplified in duplex PCR reactions, probes for the gene of interest were tagged 
to 'FAM' labelled fluorescent dyes, while GapDH probes were labelled with 'VIC' 
dye, they fluoresce at different wavelengths, allowing them to be measured in 
the  same  reaction  without  interference.  Reactions  were  performed  in  5   l 
volumes in 384 well plates.  The reaction constituents and temperature cycling 
parameters were: 
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Reaction Mixtures:    5µl: 
          Vol.( l) 
2X Genotyping Master Mix   2.5 
20X Gene Expression Assay    0.25 
20X GapDH Expression Assay  0.25 
cDNA          2.0 
Temperature cycling: 
50°C  2 min 
95°C  10 min 
95°C  15 sec 
60°C  1 min 
All  samples  were  amplified  in  triplicate,  at  least  three  treatment  replicates 
were included per experiment.  Fluorescence of FAM and VIC dyes was measured 
for  all  reactions  during  temperature  cycling,  data  was  analysed  using  a 
combination  of  Applied  Biosystems  SDS  (Sequence  Detection  Software)  and 
Microsoft Excel software.  SDS plotted amplification curves as cycle number vs. 
fluorescence  for  both  dyes  in  every  well.    FAM  and  VIC  fluorescence  were 
analysed as separate data sets, a fluorescence threshold was identified for each 
data set where amplification curves were in their exponential phase.  The 'cycle 
threshold  value'  (Ct  value)  for  each  amplification  curve  was  interpolated  by 
finding the precise fractional cycle number (to 5 decimal places) at which the 
curve crossed the fluorescence threshold. Ct values for FAM and VIC data were 
exported  from  SDS  as  text  files  and  converted  to  Excel  documents  for  data 
analysis.    Relative  levels  of  gene  expression  were  calculated  by  the  '  Ct 
method'  (Livak  KJ  &  Schmittgen  TD.  2001).    This  method  calculates  gene 
expression normalised to the endogenous control relative to a calibrator from 
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within  the  experiment  (i.e.  a  sample  or  sample  group  designated  to  have 
relative gene expression level of 1.0), it is advantageous because it does not 
require the inclusion of a standard curve from a serial dilution of template in 
each experiment.  The   Ct method is logically derived from the equation that 
dictates the rate of product accumulation during PCR: 
For  Gene  Expression  Assays  designed  by  Applied  Biosystems  the  efficiency  is 
close to 1, therefore the amount of target can be calculated as: 
Relative quantification (RQ) = 2
   Ct 
In order to use the   Ct it was imperative to experimentally confirm that the 
amplification efficiencies of the target and control gene PCRs were the same 
(i.e.  that  EX  =  ER).    Therefore  the  amplification  efficiencies  of  each  Gene 
Expression Assay were measured in duplex PCRs with the GapDH assay using a 
serial dilution of template. This process was performed for all Gene Expression 
Assays  and  Custom  Gene  Expression  Assays  for  each  different  cDNA  template 
(e.g. for cDNA from kidneys, carotid arteries and for each cultured cell line). A 
dilution series of cDNA template was prepared from neat to 1/1,000, typically 
including  1/5,  1/10,  1/50,  1/100,  1/500  and  1/1000  dilutions.  Graphs  were 
plotted  of  log  (dilution)  versus  Ct  for  the  target  template  and  GapDH,  the 
gradient  of  each  line  was  compared,  according  to  the  Applied  Biosystems 
guidelines they had to be within ±0.1 to be used to measure gene expression in 
this tissue. Each Gene Expression Assay for RNA from each tissue in this project 
passed this test. 
2.6.3   Functional experiments of hyperterophy in the Primary cells 
2.6.3.1  Neonatal cardiomyocyte & fibroblast isolation 
Isolation  of  primary  cardiomyocytes  and  fibroblasts  took  place  from  neonatal 
whole hearts.  After dissection, the hearts were placed in 1x ADS buffer (per 
litre).  
1x ADS Buffer 
NaCl    6.8g     (S9888) Wendy Crawford    56 
HEPES   4.76g     (H4034) 
NaH2PO4   0.12g     (S3139) 
Glucose   1.0g     (G7528) 
KCl     0.4g    (P3911) 
MgSO4    0.1g    (M2643) 
Made up to 1 litre with MilliQ water, pH to 7.35 with NaOH, sterilised and stored 
at 4
oC. 
Each heart was checked to remove excess connective tissue and surrounding fat, 
and gently squeezed to remove excess blood, and blood clots removed.  The 
cleaned  hearts  were  transferred  to  a  clean  dish  containing  1x  ADS  buffer 
(enough to just cover the hearts).  The hearts were chopped until homogenised 
using ‘spring bow’ scissors (tissue pieces should be small enough to pass through 
the tip of Pasteur pipette) and transferred to a Duran bottle along with the 1x 
ADS buffer.  Small pieces of the tissue in the plate were washed off with fresh 
ADS and transferred to a Duran bottle.  The tissue was digested in a number of 
stages, using a shaking water bath to incubate.  The enzyme mix used to digest 
the tissue was made as follows: 
Enzyme mix 
Collagenase Type 2     0.03g    LS0004176 
Pancreatin (porcine)  0.03g    P3292 25G 
The constituent parts were weighed into two separate 50 ml Falcon tubes and 20 
ml 1xADS buffer was added to each.  They were then vortexed to dissolve the 
powder, and filter sterilised using syringe filters (0.2µm; 1 per ~15 ml).  The 
filtered enzyme was placed in a sterile 100 ml Duran bottle and both falcons 
were ‘washed’ with a total volume of 10 ml of 1x ADS, and filter sterilized. Wendy Crawford    57 
There are 6 stages of digestion which are listed below with their appropriate 
conditions. 
Digest 
Volume of the 
enzyme mix 
(ml) 
Time (min) 
Speed 
(strokes/min) 
1  10  5  180 
2  10  20  160 
3  8  25  150 
4  8  25  150 
5  6  15  160 
6  6  10  150 
 
The Duran bottle was removed from the water bath and placed in the hood. The 
chopped tissue was allowed to settle, and the supernatant was removed and 
discarded.  For each subsequent stage, the supernatant was removed and placed 
in a sterile falcon tube containing 2ml foetal calf serum (FCS), and centrifuged 
at 1000rpm for 5 minutes.  The supernatant was discarded, and the pellet re 
suspended  in  4  ml  FCS.    The  cell  and  supernatant  mix  was  placed  in  the 
incubator with the lid of the falcon loosened to allow CO2 to reach the cells.  
This  was  repeated  until  step  5.    After  step  6  in  the  digestion  protocol,  the 
supernatant was added to the re suspended cells, and centrifuged at 1000rpm 
for  6  minutes.    The  supernatant  was  removed  carefully  and  the  pellet  re 
suspended in plating media (4 ml media per 10 hearts). 
Pre-plating (to remove adherent non-myocytes) 
The re suspended supernatant was then plated in a 60 mm primaria dish, and 
incubated for 1 hour at 37
oC, 5% CO2 to allow the cardiac fibroblasts to adhere 
to the plate surface.  The cardiomyocytes remain in suspension.  The floating 
cardiomyocytes were then washed to separate them from the fibroblasts.  The 
media was used to wash the surface of the plate using a Pasteur pipette, and 
transferred to a clean 50 ml falcon.  Fresh plating media was then applied, and Wendy Crawford    58 
used to wash, and repeated as necessary, checking after each wash to ensure 
the cardiomyocytes had been removed.  The plating media was replaced after 24 
hours  with  maintenance  media,  which  is  serum  free  to  reduce  the  potential 
contamination with fibroblasts. 
Plating media 
      ml    cat no 
DMEM     340    42430025 (Invitrogen) 
M199      85    2340020 (Invitrogen) 
Horse serum   50    SCHFRA2052Hi (Autogen Bioclear) 
Foetal calf serum  25    7.01 (Autogen Bioclear) 
Pen Strep    5    15140122 (Invitrogen) 
(10,000U/ml Penicillin) 
(10,000ug/ml Streptomycin) 
 
Maintenance media 
      ml 
DMEM     400 
M199      100 
Pen Strep (*100)  5 
(10,000U/ml Penicillin) 
(10,000ug/ml Streptomycin) Wendy Crawford    59 
Serum Free media 
        ml 
DMEM       485 
Pen Strep      5 
(10,000U/ml Penicillin) 
(10,000ug/ml Streptomycin) 
L Glutamate (200 mM)  5 
Sodium pyruvate (100 mM)  5 
All media was stored at 4
 oC 
1% (w/v) Gelatine Solution 
5g in 500ml milliQ water, autoclave and store at 4
oC. 
Gelatine (porcine skin) Type A, Sigma cat no. G1890 (100g) 
Gelatine coating the dishes 
1ml of 1% (w/v) gelatine was added to each of the 24 well, swirled to coat the 
bottom of the well, and the excess gelatine removed and returned to the bottle.  
The plates were air dried in the hood for at least 2 hours. 
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2.6.3.2   Hypertrophy assay of cardiomyocytes with ANG II 
stimulation 
A 24 well plate was coated in 1% (w/v) gelatine and allowed to dry.  The wells 
were  seeded  at  1x10
5  density  with  cardiomyocytes,  in  plating  media  and 
incubated at 37
oC overnight.  The media was changed to serum free media after 
24 hours.  The cardiomyocytes were stimulated with Angiotensin II at a range of 
concentrations from 50nM up to 200nM and incubated at 37
oC for 24 hour.  The 
cells were washed twice with PBS, and 700ul of Qiazol was applied to each well, 
and the cells were scraped into solution.  RNA was then extracted (2.2.1), and 
Gene expression of the stimulated cardiomyocytes was measured using Taqman 
qRT PCR. 
2.6.3.3   Phalloidin staining (to visualise f-actin) 
The cardiomyocytes were washed twice with PBS (Lonza), and excess PBS was 
aspirated.  100 l of 4% (w/v) PFA was applied to the cells for 20 minutes at room 
temperature to fix the cells.  The cardiomyocytes were washed twice with PBS 
(Lonza), and excess PBS was aspirated.  The cells were then permeabilzed with 
0.1% (v/v) TritonX 100 for 20 minutes at room temperature, and washed twice 
with PBS (Lonza), and excess PBS was aspirated.  100 l phalloidin (5 g/ml in 1% 
(v/v)  BSA)  solution  per  well  was  added,  and  incubated  for  1hour  at  room 
temperature,  protected  from  light.    The  cardiomyocytes  were  washed  twice 
with PBS (Lonza), and excess PBS was aspirated.  The cells were measured using 
the microscope. 
2.6.3.4   Scratch assay 
Fibroblasts were passaged and allowed to expand.  When suitable numbers were 
acquired, the cells were lifted using 10% (v/v) trypsin EDTA and were seeded at 
4x10
5 cell density in a 12 well plate, in triplicate and incubated at 37
oC, 5% CO2 
for 24 hours.  The cells were washed twice with PBS (Lonza) and replaced with 
serum free media to quiesce the cells and allow them to reach a synchronous 
stage of cell division.  The cells were incubated 37
oC, 5% CO2 for 48 hours and 
then washed twice with PBS (Lonza), and the media replaced contained varying Wendy Crawford    61 
concentrations of serum (0%, 1%, 5%, 10% & 20% (all v/v)).  A single scratch was 
made, using a p200 tip.  Reference marks were made on the base of the plate to 
ensure measurements at the time points were being made at the same location.  
The  wound  was  measured  at  x10  magnification  at  0  hours,  16  hours  and  24 
hours. 
2.6.3.5   MTT Cell Viability Assay 
Fibroblasts were passaged and allowed to expand.  When suitable numbers were 
acquired, the cells were lifted using 10% (v/v) trypsin EDTA and were seeded at 
1.5x10
4 cell density in a 96 well plate, in triplicate and incubated at 37
oC, 5% 
CO2 for 24 hours.  The cells were washed twice with PBS (Lonza) and replaced 
with  serum  free  media  to  quiesce  the  cells  and  allow  them  to  reach  a 
synchronous stage of cell division.  The cells were incubated 37
oC, 5% CO2 for 48 
hours  and  then  washed  twice  with  PBS  (Lonza),  and  the  media  replaced 
contained varying concentrations of serum (0%, 1%, 5%, 10% & 20% (all v/v)).  
The cells were incubated at 37
oC, 5% CO2 for 24 hours.  15 l of dye was added to 
each well, and the plate was incubated at 37
oC, 5% CO2 for 4 hours.  100 l of 
stop solution was added to each well, and the plate incubated at 37
oC, 5% CO2 
for 1 hour.  Absorbance was recorded at 570nm using the Wallmac. 
2.6.4   Statistical Analysis 
The  significance  threshold  for  all  analysis  was  set  at  0.05.  For  statistical 
comparisons between two groups, 2 sample t tests were applied. For statistical 
comparisons in data sets with more than two groups, analysis of variance was 
calculated, followed by the Dunnett's post test, comparing all samples groups 
against a designated control group. 
The Gene level analysis of the Exon array (Chapter 3) uses the False Discovery 
Rate (FDR) control, which is a statistical method used to correct for multiple 
comparisons in multiple hypothesis testing.  The use of FDR controls the number 
of incorrectly rejected null hypotheses (or Type I errors). Wendy Crawford    62 
2.6.5   Partek analysis 
Partek Genomics Suite allows data to be imported from a variety of array chip 
platforms, from many different formats, including metaprobeset files, and plain 
text  file  formats  from  one  colour  and  two colour  microarrays.    It  can  allow 
analysis  of  gene  expression,  identification  and  annotation  of  genes  and 
biomarkers of interest, and provides an informative construct of the output, to 
allow  visualisation  of  the  results.    Partek  genomics  suite  also  automatically 
provides links to NetAffx, UCSC genome browser, integrated genome browser, 
and other internet databases, which aids further analysis of the array outcomes. 
Affymetrix Exon Array 
The CEL files were uploaded to Partek, and the data was normalised using the 
RMA default algorithm (quantile normalisation and Median polish for probe set 
summarization).  The data was then transformed using PCA.  ANOVA was used to 
identify significant differentially expressed genes.  An ANOVA model, including 
pairwise contrasts and Genechip effects, was constructed using step up false 
discovery rate (FDR).  The data was filtered to allow for the minimum congenic 
interval at markers D14Rat54 (5,116,492bp) to D14Got41 (34,375,424bp). 
Illumina genome-wide expression assay 
The Illumina RatRef 12 Expression BeadChip for genome wide expression analysis 
contains in the region of 22,000 probes, selected primarily from the NCBI RefSeq 
database.  The Direct Hybridization Assay offers the highest level of multiplexing 
for  whole genome  expression  profiling  available.  With  up to date  expression 
content  and  high throughput  processing,  this  array  allows  for  the  efficient 
production of high quality data for large gene expression studies. 
The data generated was quantile normalised and the final report was generated 
from Genestudios, and this data was uploaded to Partek.  The data was then 
transformed using PCA.  ANOVA was used to identify  significant differentially 
expressed genes.  An ANOVA model, including pairwise contrasts and Beadchip 
effects, was constructed using step up false discovery rate (FDR).  
3. Affymetrix  Exon Array  analysis  in  the  heart  of 
the  stroke-prone  spontaneously  hypertensive 
rat, Wistar Kyoto and chromosome 14 congenic 
strains. Wendy Crawford, 2010          64 
3.1 Introduction 
A genome wide array, utilizing the chromosome 14a strains was inspired by the 
previous work within the department, as the genotyping and phenotyping data 
gathered had already indicated that these strains were of interest, as such a 
severe phenotype of LVMI had  been  identified  in  the  WKY.SPGla14a,  with  no 
effect  on  the  blood  pressure.    The  exon  array  was  initiated  as  part  of  a 
collaboration with Klio Maratou & Tim Aitman (Euratools), and thought to be a 
useful method of generating more information from the single array experiment, 
as  the  design  allows  analysis  on  exons  and  their  splicing,  and  also  on  gene 
transcripts.   
The exon array utilizes up to 4 probes per exon, and around 40 probes per gene 
to  enable  a  number  of  complementary  levels  of  analysis  –  exons,  Gene 
expression and alternative splicing.  The use of multiple probes per gene allows 
for  ‘exon level’  analysis,  which  allows  for  identification  of  different  isoforms 
(alternatively  spliced  forms)  of the  gene.    This  in  turn allows  the  exon level 
analysis to be applied on a whole genome scale, which enables the detection of 
specific  alterations  in  exon  usage  that  may  play  a  central  role  in  disease 
mechanism and etiology, and allows us to filter alternative splicing information.  
The second level of analysis is ‘gene level’ expression, in which the multiple 
probes  on  different  exons  are  summarized  into  an  expression  value  of  all 
transcripts from the same gene.  This allows for a comprehensive coverage of 
the genome.  The array itself has the highest resolution expression analysis, as it 
interrogates  over  850,000  exon  clusters  within  the  known  and  predicted 
transcribed regions of the entire genome. 
Splicing is the mechanism by which RNA is modified after transcription, where 
introns  are  removed  from  newly  synthesized  RNA,  and  the  exons  are  joined 
together (Jurica MS & Moore MJ. 2003).  This is required for mRNA to produce 
the correct protein through translation.  The splicing event is controlled and 
performed  by  RNA  molecules,  and  is  catalyzed  by  the  spliceosome.    The 
spliceosome  is  a  large  RNA protein  complex  containing  5  small  nuclear 
ribonucleproteins (snRNP’s)  Wendy Crawford, 2010          65 
Alternative  splicing  is  a  naturally  occurring  mechanism,  and  is  the  means  by 
which  there  is  increasing  diversity  in  structure  and  function  of proteins,  and 
functionally  distinct  mRNA’s,  and  allows  for  greater  macromolecular  and 
complexity of cells of both prokaryotic and eukaryotic organisms (Blencowe BJ. 
2006).    Viruses  utilize  alternative  splicing  as  a  mechanism  to  increase  their 
diversity, whilst having a relatively small genome, whilst genome wide analyses 
indicates that 40 60% of all multi exon human genes undergo alternate splicing 
(Modrek B & Lee C. 2002).  Female specific alternative splicing of Drosophila 
melanogaster  doublesex  (dsx)  pre mRNA  is  an  excellent  example  of  how 
alternative splicing can be positively controlled (Lynch KW & Maniatis T. 1996).  
The  pre mRNA  dsx  gene  contains  6  exons.  In  intron  3  of  the  dsx,  there  is  a 
nonconsensus 3’ splice site which is not recognised by the splicing machinery in 
males, meaning that exons 1 3 are directly joined to exons 5 6.  This in turn 
leads to an mRNA which encodes a transcriptional regulatory protein which is 
required for male sexual differentiation.  In females, the weak 3’ splice site is 
recognised  which  leads  to  exons  1 3  joining  onto  exon  4.    The  RNA  is  then 
polyadenylated  which  leads  to  an  mRNA  which  encodes  a  transcriptional 
regulatory  protein  which  is  required  for  female  sexual  differentiation 
(Coschigano KT & Wensink PC. 1993).  The accuracy of alternative splicing is 
important, as splicing errors are thought to contribute to about 10% of human 
genetic diseases (Garcia Blanco MA et al. 2004).  Abnormally spliced mRNAs are 
found in a high level of cancerous cells, such as BRCA1.  Many of BRCA1’s splice 
variants arise from mutations in consensus intronic splice donor and acceptor 
sites  (Tesoriero  AA  et  al.  2005).    Cystic  Fibrosis  (CF)  has  been  linked  to 
mutations  in  either  cis acting  elements  or  trans acting  factors  which  lead  to 
abnormal splicing.  13 20% of the known 1200 CF disease causing mutations are 
thought  to  affect  splicing,  and  alternative  splicing  in  the  CF  gene  may  also 
influence disease severity (Chu CS et al. 1993).  
The data generated should provide us with a depth of knowledge of the congenic 
region of the chromosome 14 strains, and provide information on disease causing 
mechanisms in these strains.  As alternative splicing has such a potential impact 
on the initiation of so many diseases, the exon level analysis was included as this 
had  not  been  investigated  previously  in  the  SHRSP,  WKY  WKY.SPGla14a  and 
SP.WKYGla14a.   Wendy Crawford, 2010          66 
3.2 Methods 
The  Affymetrix  exon  array  was  carried  out  in  full  by  Dr  Klio  Maratou  and 
Professor Tim Aitman of Imperial College London as part of a collaboration under 
the auspices of Euratools.   
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3.3 Results 
3.3.1   Single Nucleotide Polymorphism analysis of SHRSP and WKY  
Single  Nucleotide  Polymorphisms  (SNPs)  were  analysed  through  the  STAR 
consortium,  whose  main  aim  was  to  generate  a  haplotype  map  of  the  rat 
genome, and to present this in such a way to facilitate QTL gene identification 
(Saar K et al. 2008).  The genotyping was achieved by utilising Affymetrix and 
Illumina platforms to align the SNP genotyping assays of SHRSP and WKY strains 
from the Glasgow breeding programme, alongside 167  of the most commonly 
used inbred rat lines.  
   
Figure  3.1  Schematic  diagram  of  Single  Nucleotide  Polymorphism  haplotype  RGD  analysis  of 
SHRSPGla and WKYGla rat DNA 
A)  Shows  a  broad  overview  of  chromosome  14  (5-34Mb),  and  B)  is  showing  a  more 
detailed view of the 5-9Mb region.  SNP’s are annotated in red and show changes relative 
to SHRSPGla.  The SHRSPGla and WKYGla strains are located at the bottom of the 
diagram as indicated by the arrows to the left of the diagram.  The alignment shows the 
differences  and  similarities  between  the  Glasgow  (Gla)  strains  and  those  from  other 
breeding programmes, and also if SNP’s are present.   
 
 
Chromosome 14 5-9Mb 
Chromosome 14 5-34Mb 
A 
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Figure 3.1A shows that the 5 9Mb region on chromosome 14 has a high density of 
SNPs which is interesting as the QTL for Left Ventricular Mass Index (LVMI) is in 
this region (Figure 1.5).  Congenic breeding to allow the introgression of a 29Mbp 
section of the SHRSP onto the WKY background, and a 102Mbp section of the 
WKY onto the SHRSP background has been established, and the strains have been 
confirmed by genotyping. 
3.3.2   Exon array of 5 week Chromosome 14 animals  
The exon array was carried out and filtered on the minimal congenic interval 
(29Mbp). Chromosome 14a congenic strain animals were analysed, along with the 
parental  SHRSP  and  WKY  strains,  to  investigate  the  potential  for  SNP’s  and 
alternative splicing in the QTL for LVMI (Figure 3.2).  The data was filtered using 
a venn diagram, and the resulting area of intersect for the four strains indicates 
exons  which  are  common  (Figure  3.2).    Fifty  nine  exons  were  differentially 
expressed across all 4 strains, of which 26 have a gene assignment.  This led to 
14 annotated genes to be investigated further (Table 3.1).  The resulting exon 
data for each strain was filtered to identify expression changes related to exons 
(Table 3.2).  As there are up to 4 probes per gene in the exon array, many of the 
genes assignments have duplicates, which could mean it is an overall change in 
the transcript causing the change in the exon array.  Because of this, Clock has 
been isolated for further investigation as it has only one probeset showing a 
difference  in  the  exon  array  and  has  also  been  identified  by  the  alternative 
splicing analysis.  The Clock gene is of particular interest, as it is located on 
chromosome  14,  and  is  a  circadian  rhythm  associated  gene  (Young  M  et  al. 
2001).   
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Figure 3.2 Venn diagram illustrating exon analysis of the SHRSP, WKY and chromosome 14 congenic 
strains 
Venn  diagrams  illustrating  exon  array  results  in  the  heart  in  5  week  SHRSP,  WKY, 
SP.WKYGla14a  and  WKY.SPGla14a  rats.  The  number  of  probesets  significantly 
differently expressed in each pairwise comparison are shown. 
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Table 3.1 Tables showing the output files from exon array 
Table shows the output from the exon array anlysis, indicating the 26 exons which have 
gene assignments.  These 26 gene assignments equate to 14 individual genes.   
 
 
The signal intensity of the microarray probes is a relative measure of expression 
of  the transcript.    SHRSP  and  WKY  congenic  strains  display  a  higher  level  of 
signal  intensity  than  the  WKY  and  SHRSP  congenic  strains  at  exon  8  (Figure 
3.3B).  This would suggest that exons may be spliced out of the WKY strain and 
SHRSP congenic strain in the Clock gene at exon 8. 
 
 
 
Probeset ID  Accession number 
 
Gene assignment 
 
Chromosome locus 
5959530  XR_008179  RGD1565568_predicted  14: 5,888,451 5,945,589 
6437639  XR_008179  RGD1565568_predicted  14: 5,888,451 5,945,589 
6723207  XR_008179  RGD1565568_predicted  14: 5,888,451 5,945,589 
6015233  XM_573551  RGD1565568_predicted  14: 5,888,451 5,945,589 
6581067  XM_223745  LOC305633  14: 13,013,956 13,107,467 
6649219  XM_223745  LOC305633  14: 13,013,956 13,107,467 
6618452  XM_001073390  Ripx  14: 21,011,631 21,086,603 
6580114  NM_021856  Clock  14: 34,218,466 34,258,054 
5858860  NM_012946  Sparcl1  14: 6,766,346 6,797,580 
6484105  NM_012946  Sparcl1  14: 6,766,346 6,797,580 
6203753  NM_001108357  Mobkl1a_predicted  14: 20,911,418 20,944,224 
6579583  NM_001108357  Mobkl1a_predicted  14: 20,911,418 20,944,224 
6580066  NM_001108355  Cnot6l_predicted  14: 14,924,620 15,011,984 
6544056  NM_001107206  Aff1_predicted  14: 7,015,191 7,114,671 
6433275  NM_001107205  RGD1564709_predicted  14: 5,950,942 5,998,413 
5659947  NM_001017496  LOC498335: Cxcl13  14: 15,126,337 15,131,368 
5761726  NM_001017496  LOC498335: Cxcl13  14: 15,126,337 15,131,368 
5935782  NM_001017496  LOC498335: Cxcl13  14: 15,126,337 15,131,368 
6042163  NM_001017496  LOC498335: Cxcl13  14: 15,126,337 15,131,368 
6685998  NM_001017496  LOC498335: Cxcl13  14: 15,126,337 15,131,368 
6695863  NM_001014133  LOC360910: Abcg3l2  14: 5,573,149-5,613,575 
5682078  NM_001004209  Dhrs8  14: 6,859,573 6,891,510 
5850797  NM_001004209  Dhrs8  14: 6,859,573 6,891,510 
5785795  NM_001004076  Abcg3  14: 6,235,275 6,289,605 
6040515  NM_001004076  Abcg3  14: 6,235,275 6,289,605 
6214440  ENSRNOT00000003472  Cipar1  14: 18,046,002 18,078,330 Wendy Crawford, 2010          71 
Table 3.2 Alternative splicing analysis of the Affymetrix exon array output data 
The alternative splicing outcome is detailed, which indicates 6 genes showing evidence of 
alternative splicing.  Clock gene is common to both sets of analysis (highlighted in red). 
Transcript ID  Accession number  Gene_assignment  Chromosome locus 
7123570  NM_001017496  LOC498335: Cxcl13  14: 15,126,337 15,131,368 
7116203  NM_001004209  Dhrs8  14: 6,859,573 6,891,510 
7122910  NM_001107206  Aff1_predicted  14: 7,015,191 7,114,671 
7117187  NM_001107212  Adamts3_predicted  14: 19,756,887 19,963,451 
7122822  ---     
7117864  NM_021856  Clock  14: 34,218,466 34,258,054 
7117158  NM_001105999  Ankrd17  14: 19,248,809 19,387,059 
 
 
 
Figure 3.3 A schematic view of the Clock exon array analysis. 
A) Positioning of the PCR primers relative to exons on the ORF of Clock gene.  The 
primers can be used in a variety of F & R combinations.  B) Comparison of the signal 
intensity from the exon array of the parental and congenic strains. 
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3.4 End point PCR and DNA sequencing to investigate 
alternative splicing in the Clock gene 
Primers were designed for end point polymerase chain reaction (PCR) to cover 
the  predicted  alternatively  spliced  exon  8  region  in  the  Clock  open  reading 
frame  (ORF).    Primer  positions  are illustrated, and  show  the  region  between 
exons 4 14 was included in the design to ensure full coverage of the expected 
splice site (Figure 3.3A).  PCR products were amplified using the SHRSP and WKY 
parental strains and the chromosome14a congenic strains on heart cDNA.  The 
primers were used in their numerical pairs (primer pair 1F &1R, 2F & 2R and 3F 
& 3R), and also in combination to identify PCR products covering the splice site 
was produced (using primers 1F & 2R and 1F &3R).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Clock Primer PCR products  
Amplified PCR products from Clock ORF in biological replicates of SP, WKY.SPGla14a, 
SP.WKYGla14a, and WKY cDNA with the primer pairs as illustrated, electrophoresed on 
a 1% agarose gel. 
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The bands obtained are of the expected size for all the primer pairs, and clearly 
show no alternative splicing is occurring in the ORF of the Clock gene (Figure 
3.4).  The congenic strains show a lower intensity of PCR product.  A full list of 
expected  sizes  of  PCR  products  is  available  as  a  supplementary  table  in  the 
appendix.  To further investigate potential alternative splicing in the ORF of the 
Clock gene, the SHRSP, WKY, SP.WKYGla14a and WKY.SPGla14a  PCR products 
were sequenced, and the resulting template was read using the ABI 3700.  Data 
were  analysed  using  Seqscape  v2.1  to  align  the  sequence  derived  from  the 
sequencing reaction with the draft genome sequence of the Brown Norway strain 
(Figure3.5A). 
 
 
 
Figure 3.5 Sequence analysis of Clock PCR products 
A) Sequence alignment of Clock PCR products of each of the 4 strains analysed.  The SNP 
identified at +432bp upstream of the initiator ATG codon is shown.  BN indicates the 
Brown  Norway  reference  sequence  to  which  the  generated  sequence  has  been  aligned.      
B)  The  positioning  of  the  SNPs  identified  in  the  ORF  of  the  Clock  gene,  and  the 
differences when comparing the sequence derived from the PCR products with that of the 
Brown Norway.  It also indicates if any amino acid changes have occurred as a result of the 
SNP.   
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                    Y 
WKY   421 TTACTTGAACAcTTACCATCTGATCTTGTGGATCAAAGTATATTTAATTTTATCCCAGAG 
SP    421 TTACTTGAACAtTTACCATCTGATCTTGTGGATCAAAGTATATTTAATTTTATCCCAGAG 
      141 -L--L--E--H--L--P--S--D--L--V--D--Q--S--I--F--N--F--I--P--E- 
 
                                                                    
WKY   481 GGAGAACATTCAGAGGTTTATAAGATACTATCTACTCACCTGCTGGAAAGTGACTCCTTA 
SP    481 GGAGAACATTCAGAGGTTTATAAGATACTATCTACTCACCTGCTGGAAAGTGACTCCTTA 
      161 -G--E--H--S--E--V--Y--K--I--L--S--T--H--L--L--E--S--D--S--L- 
 
                                                                    
WKY   541 ACCCCCGAGGACTTAAAATCAAAAAATCAGTTAGAATTCTGTTGTCACATGCTTCGAGGA 
SP    541 ACCCCCGAGGACTTAAAATCAAAAAATCAGTTAGAATTCTGTTGTCACATGCTTCGAGGA 
      181 -T--P--E--D--L--K--S--K--N--Q--L--E--F--C--C--H--M--L--R--G- 
 
                                                                    
WKY   601 ACAATAGACCCAAAGGAGCCATCCACCTATGAATATGTGAGATTTATAGGAAATTTTAAA 
SP    601 ACAATAGACCCAAAGGAGCCATCCACCTATGAATATGTGAGATTTATAGGAAATTTTAAA 
      201 -T--I--D--P--K--E--P--S--T--Y--E--Y--V--R--F--I--G--N--F--K- 
 
                                                                    
WKY   661 TCTTTAAACAGTGTATCAACTTCAACACATAATGGTTTCGAAGGAACTATACAGCGCACA 
SP    661 TCTTTAAACAGTGTATCAACTTCAACACATAATGGTTTCGAAGGAACTATACAGCGCACA 
      221 -S--L--N--S--V--S--T--S--T--H--N--G--F--E--G--T--I--Q--R--T- 
 
                                                                    
WKY   721 CACAGGCCTTCTTATGAAGATAGAGTTTGTTTCGTAGCTACTGTCAGATTAGCTACCCCT 
SP    721 CACAGGCCTTCTTATGAAGATAGAGTTTGTTTCGTAGCTACTGTCAGATTAGCTACCCCT 
      241 -H--R--P--S--Y--E--D--R--V--C--F--V--A--T--V--R--L--A--T--P- 
 
                                             R                         
WKY   781 CAGTTCATCAAGGAAATGTGTACTGTTGAAGAACCgAATGAAGAGTTCACATCTAGACAC 
SP    781 CAGTTCATCAAGGAAATGTGTACTGTTGAAGAACCaAATGAAGAGTTCACATCTAGACAC 
      261 -Q--F--I--K--E--M--C--T--V--E--E--P--N--E--E--F--T--S--R--H- 
 
                                                                    
WKY   841 AGTTTAGAATGGAAGTTTCTATTTCTAGATCACAGGGCGCCGCCAATCATAGGCTATCTG 
SP    841 AGTTTAGAATGGAAGTTTCTATTTCTAGATCACAGGGCGCCGCCAATCATAGGCTATCTG 
      281 -S--L--E--W--K--F--L--F--L--D--H--R--A--P--P--I--I--G--Y--L- 
 
Figure 3.6 SNP positioning within the ORF of the Clock gene. 
The sequence shows the SNP’s as identified previously (Figure 3.5).  The letters in the 
rows labelled WKY have a 2 colour system of blue and black showing where the exons are 
located.  The yellow highlighting indicates the amino acid codon.  The original base is 
highlighted in green, with the change in lower case letters. 
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Two SNPs were identified within the coding region of the Clock gene, which do 
not cause a change in amino acid (Figure 3.6).  This may explain the difference 
in signal intensity in the exon array analysis, as base pair mutations may prevent 
the binding of the exon specific probes.  On further investigation of the Clock 
gene  via  ensembl,  it  was  noted  that  the  exon  array  had  misguided  the 
identification of exon 8 as being alternatively spliced, and exon 9 was actually 
the target.  The PCR primers were extended in their design to cover a region of 
the ORF, and this indicated the SNP in exon 5.  To confirm the exon probes’ 
location in relation to the SNPs, an alignment was made of the probes to the 
Clock gene sequence.  The probe ID’s were identified from the NetAffx website, 
and were confirmed using ensembl, ensuring the correct probe was covering the 
exon  (Figure  3.7).    The  probe  sequence  was  then  aligned  using  Integrated 
genome  browser  (Nicol  JW  et  al.  2009)  (Figure  3.8).    The  positioning  of  the 
probes for 6580114 over the SNP (+816) suggests that the lower signal intensity 
detected in exon 9 is due to the probe not binding as efficiently to this region, 
consistent with the PCR analysis.  The analysis of the Affymetrix exon array data 
then focussed on the minimum congenic interval of the chromosome 14a strains 
(29Mbp) and the gene level analysis was then carried out (genome wide scan) to 
identify positional candidates in the SHRSP, SP.WKYGla14a, WKY.SPGla14a and 
WKY strains. Wendy Crawford, 2010          76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Ensembl schematic of Clock gene, showing the exons. 
The screenshot from Ensembl shows the exon arrangement of Clock ORF.  The numbers outlined in red refer to the probe ID’s for the exon array 
obtained from the NetAffx website.  The probes are in the location of the regions containing the SNPs. 
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Figure 3.8 Location of Clock exon probes used in the array. 
A)The exon probes for 6482811 were identified and aligned with the Clock ORF using 
IGB.  The 25-mer probes are shown (thick lines under the sequence), along with their 
position on chromosome 14.  The SNP (+432 C/T) lies outside the area of the probes.  
B)The exon probes for 6580114 were identified and aligned.  The probes position is shown 
on the alignment, along with their chromosome location.  The probe sequence is translated 
to the reverse compliment (labelled sense), and the position of the SNP (+816 G/A) is 
shown, relative to it’s position on the probe. 
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3.5 Gene level analysis  
The transcript level analysis of the exon array was carried out, and the data 
were analysed by filtering to the minimum congenic interval (29Mbp) and to the 
genome  wide  scan.    5  week  old  SHRSP,  WKY  and  Chromosome  14a  congenic 
strain animals were analysed, along with the parental SHRSP and WKY strains at 
the  5  week  time  point,  to  investigate  the  potential  for  differential  gene 
expression.  The resulting data for each strain were filtered in a venn diagram, 
and the resulting area of intersect for the four strains indicates genes which are 
common (Figure 3.9).  The genes indicated by the overlay are Chemokine ligand 
13 (Cxcl13)   SPvWKY fold change = 2.9 and ATP Binding Cassette, sub family G 
(Abcg3)   SPvWKY fold change = 1.4 
 
 
 
 
 
 
Figure 3.9 Venn Diagram of minimum congenic interval analysis of the Exon microarray 
Venn diagrams illustrating microarray results of heart gene expression in 5 week SHRSP, 
WKY,  SP.WKYGla14a  and  WKY.SPGla14a  rats.  The  number  of  probesets  from  the 
minimum  congenic  interval  (29Mbp)  which  are  showing  significance  in  differential 
expression in each pairwise comparison are shown. 
The genome wide scan of the exon array has provided only a small number of 
gene  targets.    The  comparison  is  made  between  WKY  v  SHRSP,  and 
SP.WKYGla14a v SHRSP.  From this analysis, the following have been identified: 
Ckap21, a chromosome 3 gene, and Cxcl13.  On the basis of the data from the 
minimum congenic interval (Figure 3.9) and the genome wide scan, Cxcl13 and 
Abcg3  were  investigated  further.    All  other  genes  identified  by  pairwise 
comparisons of the minimum congenic interval are listed (Table 3.3) 
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Table 3.3 Genes identified in minimum congenic interval analysis 
Table shows the results of the exon array, displaying the genes which are identified as 
being differentially expressed in each pairwise comparison, within the minimum congenic 
interval. 
Comparison  Probe ID  Gene 
Annotation 
Chromosome locus 
SPvSP.WKYGla14a  7116203  Hsd17b11  14: 6,859,573 6,891,510 
SPvSP.WKYGla14a  7124689  LOC498350  14: 33,403,956 33,446,249 
SPvWKY  7117751  RGD1359460  14: 33,107,963 33,123,992 
(SPvWKY)v 
(SPvSP.WKYGla14a 
7117187  Adamts3  14: 19,756,887 19,963,451 
 
The genes identified are of interest as they are located within the minimum 
congenic interval, however, they appear to have no apparent functional link to 
LVMI.    Their  functions  are  as  follows:  Hsd17b11,  a  substrate  which  has  been 
implicated in supporting gestation and modulating γ aminobutyric acid receptor 
activity,  and  is  located  in  the  QTL  for  body  weight  (Chai  Z  et  al  2003); 
LOC498350 is similar to testicular haploid expressed gene product isoform 2, and 
is  found  in  the  blood  pressure  QTL;  RGD1359460  encodes  for  the  MMR_HSR1 
domain containing protein; and Adamts3 is a disintegrin and metalloproteinase 
with  thrombospondin  motifs.    The  protein  encoded  by  this  gene  is  a  major 
procollagen  II  N propeptidase,  and  a  deficiency  of  this  protein  may  be 
responsible  for  dermatosparaxis  in  animals,  which  is  a  genetic  defect  of 
connective tissues, causing skin fragility (Le Goff et al 2006).  
3.5.1   Validation of Cxcl13 & Abcg3 using qRT-PCR 
The  gene  level  analysis  indicated  Cxcl13  and  Abcg3  as  potential  positional 
candidate  genes,  and  the  results  were  validated  by  qRT PCR.    Cxcl13  mRNA 
expression,  relative  to  SHRSP  in  hearts  from  5  week  old  rats  showed 
approximately 2.5 fold higher expression in SP.WKYgla14a  relative to SHRSP, 
and approximately 2 fold higher expression in WKY relative to WKY.SP.gla14a 
(Figure 3.10A).  In hearts of 16 week old rats, Cxcl13 mRNA expression, relative 
to  SHRSP,  showed  approximately  3  fold  higher  expression  in  SP.WKYgla14a 
relative to SHRSP, and approximately 7 fold higher expression in WKY relative to 
WKY.SP.gla14a (Figure 3.10C).  Expression of Abcg3 mRNA relative to SHRSP in 
hearts  from  both  5  +  16  week  old  rats  showed  no  change  in  expression 
SP.WKYgla14a  relative  to  SHRSP,  and  no  change  in  WKY  relative  to 
WKY.SP.gla14a (Figure 3.10B + 3.10D).  Comparisons were analysed using the 
student’s  pairwise  t test.    Experimental  data  for  Abcg3  did  not  validate  the 
findings from the microarray (Figure 3.9). 
The qRT PCR results confirm the findings from the minimum congenic interval 
analysis of expression of Cxcl13 at the 5 and 16 week of age time point (Figure 
3.10).  The increased size of the error bars is due to technical variation within 
the samples.  Further investigation of the Cxcl13 gene was carried out through 
sequencing, both of the coding region and the regulatory regions.   
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Figure  3.10  qRT-PCR  of  Cxcl13  and  Abcg3  in  5  week  and  16  week  SHRSP,  SP.WKYGla14a, 
WKY.SPGla14a and WKY strains 
Expression is shown as an RQ value of SHRSP.  A) Cxcl13 has a significantly increased 
level  of  expression  in  SP.WKYGla14a  relative  to  SHRSP  and  in  WKY  relative  to 
WKY.SPGla14a  at  5  weeks  C)  and  also  16  weeks.    B)  No  significant  increase  in 
expression  of  Abcg3  in  SP.WKYGla14a  relative  to  SHRSP  and  in  WKY  relative  to 
WKY.SPGla14a at 5 weeks D) and 16 weeks. n-4 *p<0.05 
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3.5.2   Sequencing of the coding and regulatory regions of Cxcl13 
Primers for end point PCR were designed to investigate the full open reading 
frame  (ORF),  2500bp  of  the  5’  promoter  region  for  Cxcl13  and  the  3’ 
untranslated  region  (UTR)  OF  Cxcl13.    The  PCR  was  carried  out  using  the 
parental strains and the spontaneously hypertensive rat (SHR) on liver cDNA with 
the ORF primers, and on genomic DNA with the promoter and 3’ UTR primers.  
To validate the amplification products generated, the SHR, SHRSP and WKY PCR 
products  were  sequenced  and  read  using  the  ABI  3700.    This  data  was  then 
analysed using Seqscape v2.1 to align the sequence derived from the sequencing 
reaction  with  the  Brown  Norway  strain.    The  sequence  generated  was 
additionally analysed by Transfac analysis, which is a unique knowledge base 
containing  data  on  transcription  factors,  their  experimentally proven  binding 
sites, and regulated genes. It can be used to search DNA sequences for potential 
transcription factor binding sites.  A zPicture alignment will also be carried out 
to  confirm  the  findings  from  the  Transfac  analysis.    zPicture  is  a  dynamic 
alignment and visualization tool that is based on blastz alignment program, and 
can be automatically submitted to rVista 2.0 to identify conserved transcription 
factor  binding  sites.    The  percentage  homology  derived  from  the  zPicture 
indicates how conserved the 2 species are in the region analysed.  As the rat and 
mouse species diverged more than a million years ago, if an area shows more 
than 50% homology, then it is defined as being well conserved. 
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Figure  3.11  Sequence  analysis  of  Cxcl13  promoter  region,  ORF  and  3’UTR.                      
A) Sequencing results of the amplified PCR products of the Cxcl13 promoter region, ORF 
and 3’UTR, and the positioning of the SNPs.  Transcription factor analysis (Transfac) is 
shown  of  the  upstream  promoter  region.    B)  A  zPicture  alignment  shows  percentage 
homology between the rat and mouse Cxcl13 upstream promoter regions.   
Table 3.4 Position of the SNPs within the Cxcl13 sequence 
The positioning of the SNP’s found is shown in a table, which illustrate that no changes 
have resulted. 
Position  from 
start codon 
Brown Norway  SHRSP  WKY  SHR 
 791  T  T  C  C 
+866  C  C       
+899  C  T  C  C 
 
 
 
 
 
-791bp
Mouse Cxcl13
Rat Cxcl13 -vs-
-2060bp
+1
ATG TGA
-791bp
C/T
100%
50%
Hepatocyte Nuclear Factor 4 (HNF4) aaaGTCCAc
aaaGTCTAc
WKY
SHRSP
+866
 /C
+899
C/T
Cxcl13
A
B
-791bp
Mouse Cxcl13
Rat Cxcl13 -vs-
-2060bp
+1
ATG TGA
-791bp
C/T
-791bp
C/T
100%
50%
Hepatocyte Nuclear Factor 4 (HNF4) aaaGTCCAc
aaaGTCTAc
WKY
SHRSP
Hepatocyte Nuclear Factor 4 (HNF4) aaaGTCCAc
aaaGTCTAc
WKY
SHRSP
aaaGTCCAc
aaaGTCTAc
WKY
SHRSP
+866
 /C
+899
C/T
Cxcl13
A
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3.5.3   Validation of receptors of Cxcl13 using qRT-PCR 
Chemokine receptors are cytokine receptors found on the surface of certain cells 
which interact,  and  their expression  in  different  cell  types  and  their  binding 
response to specific cytokines are highly variable (Murdoch C & Finn A. 2000).  
The sequencing results showed no evidence of SNP’s within the ORF, and the 
qRT PCR data has shown there is a significant increase expression of Cxcl13 in 
the strains analysed.  To investigate whether Cxcl13 was signalling through a 
potential  functional  effect  we  assessed  the  levels  of  the  postulated  Cxcl13 
receptors.  Expression of the receptors for Cxcl13, Cxcr5 (Chromosome 8), Cxcr3 
(Chromosome X) and Ccrl1 (Chromosome 8) has been quantified by Taqman qRT 
PCR relative to GapdH in hearts from 5 week old rats, in the SHRSP and WKY 
strain.  Cxcr5 is not expressed in the heart in either of the parental strains.  
Cxcr3  shows  low  levels  of  expression  in  both  SHRSP  and  WKY,  which  is  not 
statistically  different  when  comparing  the  strains  with  each  other  via  the 
students pairwise t test.  Ccrl1 shows higher levels of expression than that of 
Cxcr3, but this is not a significant change (Figure 3.12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 qRT-PCR of Cxcr5, Cxcr3 and Ccrl1 in 5 week parental strains 
Expression is shown as an RQ value of Cxcr3 SHRSP.  Expression of Cxcr3 does not 
change in WKY when compared to SHRSP.  Expression of Ccrl1 does not change in WKY 
when compared to SHRSP. n-4. 
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3.6 Discussion 
The experiments related to this chapter analysed gene level expression from the 
exon  array,  at  both  exon  level  and  transcript  level.    Subsequent  analysis 
strategies  including  sequencing,  Transfac  analysis  of  the  ORF  and  regulatory 
regions, and gene expression in SHRSP, SP.WKYGla14a, WKY.SPGla14a and WKY 
strains were applied to investigate this further.  Cxcl13 and Abcg3 were both 
implicated  in  the  gene  level  analysis  of  the  exon  array,  and  on  subsequent 
Taqman  qRT PCR  analysis,  it  was  shown  that  Cxcl13  displays  a  significantly 
higher  level  of  expression  in  SP.WKYGla14a  relative  to  SHRSP  and  in  WKY 
relative to WKY.SPGla14a (Figure 3.10).  No significant change in expression of 
Abcg3 in SP.WKYGla14a relative to SHRSP and in WKY relative to WKY.SPGla14a, 
suggesting  that  Abcg3  is  not  differentially  expressed,  and  therefore  does  not 
represent  a  positional  candidate  gene  for  LVMI  and  was  not  prioritised  for 
further analysis.  Cxcl13 was further investigated by the analysis of the ORF and 
regulatory regions to determine the presence of SNP’s.  There is evidence of a 
SNP in the 5’ upstream region ( 791 bases of the start codon, change of C/T 
(WKY/SP) of Cxcl13 which is in the Hepatocyte Nuclear Factor 4 region (HNF4) 
(Figure 3.11).  This base pair change leads to a loss of this region in Cxcl13 in the 
SHRSP.  The zPicture analysis confirms the homology between Rat and Mouse in 
the region of the transcription factor, and this would suggest that this change 
has been conserved since the 2 species diverged.  There is evidence of 2 SNP’s 
downstream  of  the  ORF.    HNF4,  along  with  the  Hepatocyte  nuclear  factor  1 
(HNF1)  binding  site,  appears  to  have  a  crucial  role  in  cell  type specific 
transcription  of  the  HNF1  gene  (Miura  N  &  Tanaka  K.  1993).    HNF4  is  also 
associated  with  a  susceptibility  to  non insulin  dependent  Diabetes  Mellitus 
(Barroso  I  et  al.  2008).    HNF1  is  a  key  transcription  factor  involved  in  the 
expression of many liver specific genes.  Analysis of the 3’ downstream promoter 
region indicated that 2 SNP’s are present (Figure 3.11). 
Cxcl13 is a small cytokine which belongs to the CXC chemokine family, and is 
also  known  as  B  lymphocyte  chemoattractant  (BLC).    Chemokines  are  a 
superfamily  of  pro inflammatory  markers  which  are  up regulated  in  the 
myocardium of patients with chronic heart failure.  It is expressed highly in the 
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lymph  node  development,  and  is  found  in  the  extracellular  space.    It  is  a 
chromosome  14  gene,  located  in  the  QTL  regions  of  mammary  carcinoma 
susceptibility,  serum  renin  concentration,  body  weight  QTL,  pristane  induced 
arthritis and non insulin dependent diabetes mellitus.  It has been reported that 
complications  associated  with  rheumatoid  arthritis  (RA),  which  include 
atherosclerosis,  increased  risk  of  MI,  stroke,  pericarditis,  endocarditis,  left 
ventricular failure, valvulitis and fibrosis are increased by 50% with the onset of 
RA, compared with healthy individuals (Aviña Zubieta JA et al. 2008).  Patients 
who suffer from non insulin dependent diabetes mellitus also have an increased 
risk  of  cardiovascular  complications,  and  this  accounts  for  up  to  50%  of  the 
deaths associated with this disorder (Chiasson JL et al. 2003). 
The chemokine family is of interest as some members have been shown to have 
an effect in cardiac remodelling after MI, such as Cxcr4, which is the receptor 
for Cxcl12 (SDF 1).  Cxcr4 has been treated selectively with AMD3100, which is a 
Cxcr4 receptor anatagonist, and the results are a reduction in infarct size and 
improved ventricular function (Proulx C et al. 2007).  There is also an association 
between changes in cytokine production and cardiovascular morbidity in renal 
and  non renal  failure  subjects.    A  SNP  found  in  the  Interleukin  6  gene, 
associated with an increase in plasma levels in patients undergoing dialysis and 
is  linked  to  coronary  artery  disease  and  high  blood  pressure  in  healthy  men 
(Humphries SE et al. 2001).  Cx3cr1, a chemokine receptor which is a component 
of  the  inflammatory  system,  has  been  identified  and  its  genotype  shows  an 
association with an increased susceptibility to cardiovascular disease (Moatti D 
et al. 2001).   
Apolipoprotein E deficient mice have been reported to have T Cell and B cell 
aggregates in segments of aortic adventitia, adjacent to atherosclerotic lesions.  
The aggregates are precursors to aortic tertiary lymphoid organs, which have a 
similar organization to lymph nodes.  This provides evidence that aorta tertiary 
lymphoid organs organize the antigen dependent T cell and B cell (auto)immune 
response  to  atherosclerosis.    Also,  smooth  muscle  cells  underlying  intimal 
plaques are activated and express the Cxcl13 and Ccl21 (Grabner R et al. 2009). 
Cxcl13 has also been implicated in the quilty effect (QE), which is a feature of 
cardiac allograft, and is suspected of being associated with acute rejection.  The Wendy Crawford, 2010          87 
main feature of the cardiac allograft is a localised lymphocytic infiltration in the 
endocardium,  which  may  also  affect  the  myocardium.    This  alloantigen 
stimulation  leads  to  an  excess  of  Cxcl13  production,  which  along  with  its 
receptor, Cxcr5, are found in the molecular pathway for both the QE and acute 
rejection (Di Carlo E et al. 2007).  Cxcl13 expression in the kidney is increased in 
aged animals, but barely detectable in young kidneys (Schiffe L et al. 2009), so 
further investigation in other tissues from the strains, and at older time points 
would clarify this.  Cxcl13 is selectively chemotactic for B cells, and interacts 
with its chemokine receptor Cxcr5 to control the organization of B cells in the 
follicles  of  lymphoid  tissues.    Receptors  are  found  selectively  on  surface  of 
target cells, and Cxcr5 is normally found on follicular dendritic cells.  Cxcl13 
receptor analysis gene expression in heart RNA was carried out using Taqman 
qRT PCR  analysis  in  SHRSP,  SP.WKYGla14a,  WKY.SPGla14a  and  WKY  strains.  
Cxcr5 mRNA analysis of the heart would suggest that it is below the level of 
detection (Figure 3.12).  The suggestion is that Cxcl13 is not binding to Cxcr5 in 
the heart tissue, which is not regarded as the typical function of this molecule, 
and would indicate that Cxcl13 is signalling through one of the novel receptors.  
The results show expression of Cxcr3 or Ccrl1 when comparing WKY to SHRSP.  
The  receptors  have  been  implicated  in  a  number  of  diseases  including 
renovascular  hypertension,  non insulin  dependent  diabetes  mellitus,  coronary 
restenosis and pristane induced arthritis.   
Ventricular wall stress stimulates brain natriuretic peptide synthesis and release 
from cardiomyocytes, and this stress can also produce an increase in the levels 
of cytokines, such as tumor necrosis factor alpha (TNF α) or interleukin 6 (IL 6), 
which amplifies the signal due to it’s pleiotropic effect (Nian M et al. 2004).  A 
possible relationship has been established between increased blood pressure and 
LVH with inflammatory activation in patients with essential hypertension.  This 
has been identified by a study of the altered profiles cytokines and receptors in 
patients  with  essential  hypertension.    A  significant  increase  in  the  levels  of 
plasma has been identified in hypertensive patients with LVH, when compared 
with non LVH group, which is thought to be as a direct result of an increase in 
blood pressure, leading to an increase in mechanical stress (Roselló Lletí E et al. 
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The  exon  array  experiment  was  designed  to  investigate  the  possibility  of 
alternative splicing in the chromosome 14 genes of the SHRSP, SP.WKYGla14a, 
WKY.SPGla14  and  WKY  strains.    The  Clock  gene  was  implicated  by  Partek 
analysis of the array, and exon array signal intensity (Figure 3.3 & 3.4B).  The 
subsequent  analysis  with  PCR  amplifications  did  not  validate  this  finding.  
However, SNPs were found in the ORF (no change in amino acid), and the exon 
probe alignment to this region of the Clock gene showed that the probes were 
located over the SNP (position + 816 in the ORF) in exon 9.  This explains the 
change in signal intensity (Figure 3.3B).  The second SNP (position + 432 in the 
ORF) in exon 5 was discovered as a by product of the PCR’s to investigate the 
change in signal intensity in exon 9.  On further analysis of the exon probes, it 
was  found  that  they  were  not  located  in  the  area  of  the  SNP.    Clock  is  a 
circadian  rhythm  gene  which  is  located  within  the  QTLs  for  blood  pressure, 
pristane  induced  arthritis,  non insulin  dependent  diabetes  mellitus  and  for 
tongue tumour susceptibility.  Normal BP measurements vary on a daily basis, 
and normotensive subjects will experience a decrease during sleep.  Circadian 
rhythm genes are of great interest in the study of LVH as they have previously 
been linked to a non dip in the ambulatory BP in hypertensive patients.  Night 
time BP is used as an excellent prognostic tool for cardiovascular mortality, and 
is also connected to target organ damage (Verdecchia P. 2000).  A model based 
on  coupling  clustering  and  binary  classification  of  genes  which  allows 
discrimination between the different levels of response, has been developed.  
Through  the  use  of  canonical  pathways,  this  has  indicated  circadian  rhythm 
genes using ingenuity pathway analysis (Hopcroft LEM et al. 2010).  This further 
supports the Clock gene and its role in BP control, and should be investigated 
further. 
The exon array indicated the potential that SNPs possess, as several have been 
located within the strains analysed, and may provide a link to the effects they 
have on disease progression.  However, the exon array provided a relatively few 
number of gene targets, which did not allow much potential for downstream 
investigation.  On the basis of this, it was decided that an Illumina array should 
follow, as this would allow full investigation into the congenic regions of the 
Chromosome  14a  rats,  and  the  effect  it  has  on  the  severe  phenotype. 
4. Illumina microarray analysis of the heart: Gene 
expression profiling in chromosome 14a congenic 
strains in neonatal, 5 week old and 16 week old 
animals Wendy Crawford, 2010          90 
4.1 Introduction 
In the previous chapter the Affymetrix exon array provided so few targets to 
follow up, and with the identification of significant phenotypic changes at early 
time points, it was decided that an Illumina microarray, which provides genome 
wide  analysis,  would  be  carried  out  with  the  incorporation  of  the  earlier, 
neonatal  time  point.    The  earlier  time  point  will  be  of  interest  as  it  should 
provide information on  causative  genes  in hypertrophy, prior  to  the onset of 
disease.  The phenotypic data, along with evidence from the literature lends 
itself to looking at gene expression at the neonatal time point, as differences 
are already established in the LVMI, Systolic BP, RWT and MPI data from the 5 
week  old  rats.    This  would  allow  identification  of  genes  which  initiate  left 
ventricular hypertrophy (LVH), and also allow identification of how those genes 
are involved in the progression of disease.  As a result of the inclusion of this 
time point, it is essential to have an understanding on the development of the 
pre natal heart, and how it changes post natal.  The heart is the first functional 
organ  in  the  body,  and  allows  for  gas  exchange  systems  to  develop  in  the 
placenta.  The pre natal heart mainly uses anaerobic glycolysis as its source of 
energy, and post natal, this will switch to aerobic metabolism of non esterified 
fatty acids as its source of energy (Kinnula VL & Hassinen I. 1977; Clark CM. 
1971).  For this transition to take place, maturation of the mitochondria must 
occur,  and  the  levels  of  fatty  acids  and  lactate  circulating  must  increase 
(Lopaschuk  GD  et  al.  1992).    Fewer  mitochondria  are  a  characteristic  of 
immature myocytes, as is lower activities of the enzymes of the tricarboxylic 
acid cycle and electron transport chain.  Total creatine and phosphocreatine, 
along with creatine kinase (CK) activity are also increased during the period of 
cardiac cell maturation.  CK catalyses creatine to convert to phosphocreatine, 
and  consumes  adenosine  triphosphate  (ATP).    Phosphocreatine  is  used  as  a 
buffering system to allow the rapid buffering and regeneration of ATP in cells 
with high levels of energy consumption.  CK is also used as a biomarker for MI.  
SHR and WKY rats have been studied at 1 day old, 11 days and 12 weeks and it 
was shown that there are significant changes in systolic, diastolic, and mean 
pressures in SHR neonates.  Heart rate and heart weight/body weight ratios also 
show an increase, and confirm that heamodynamic and physiological parameters 
of both early and advanced stages of hypertension, which are significant in adult Wendy Crawford, 2010          91 
rats, are already altered at birth (Gray SD. 1984).  Hypertrophy in the heart is a 
structural consequence of one or more factors, which include an increase in the 
number of myocytes, an increase in the size of myocytes, and the amount of 
connective tissue elements or vasculature.  Cardiac hypertrophy is a complex 
biological process which involves remodelling of the architecture of the heart, 
which may be in response to an increase in the work load.  The stimuli for this 
process appear to be both mechanical and humoral in nature.  It has also been 
shown  that  early  onset  of  LV  volume  overload,  with  hypertrophy,  leads  to  a 
delay in the switch from anaerobic to aerobic metabolism in the neonatal heart 
(Kantor PF et al. 1999).  As the neonatal SHR rats are exposed to elevated blood 
pressures,  development  of  cardiac  hypertrophy  may  only  be  temporally  and 
quantitatively  accelerated.    Studies  have  shown  that  haemodynamic  changes 
account  for  only  a  small  proportion  of  the  left  ventricular  mass  (LVM)  and 
genetic  effects  may  be  of  greater  influence.    It  has  been  proven  that  gene 
expression is heritable and genetic control of transcription can have an effect on 
both physiological traits and disease phenotype (Hubner N et al. 2005).  Gene 
transcription in the heart is also heritable, and is thought that this may have a 
role in the control of LVM regulation (Petretto E et al. 2006). 
The  neonatal  time  point  will  be  investigated  through  a  genome wide  gene 
expression profiling.  The Illumina RatRef microarray uses in the region of 22,500 
probes for analysis of expression profiling.  The direct hybridization assay utilises 
gene  specific  probes,  which  are  designed  using  a  multi step  algorithm  to 
optimize  several  parameters  including  a  lack  of  similarity  to  other  genes, 
absence of highly repeated sequence in the genome, sequence complexity, self 
complementarity  for  hairpin  structure  prediction,  melting  temperature  for 
hybridization uniformity and distance from 3’ end of the transcript.  The bead 
system  uses  oligonucleotides,  immobilized  in  microwells  and  randomly 
distributed across the array substrate.  A 60 mer address sequence on each bead 
is used for a hybridization based procedure to map the array, and operates with 
a  single  probe  per  gene,  which  is  in  contrast  to  the  Affymetrix  exon  array, 
utilising up to 4 probes per gene.   
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Previous  measurements  from  our  laboratory  in  neonatal  rat  hearts  taken  at 
sacrifice demonstrate differences in heart weight/body weight ratio in SHRSP 
and also in the chromosome 14 congenic strains.  Although the results are not 
significant, there is a trend towards heavier hearts in SP.WKYGla14a compared 
to  SHRSP,  and  WKY  weighing  more  than  WKY.SPGla14a  (Figure  4.1A).    Body 
weight  does  not  change  across  the  4  strains  (Figure  4.1B),  when  the  heart 
weight/body ratio is considered, the same trends are observed (Figure 4.1C).  
Only  WKY  heart  weight/body  weight  ratio  is  significantly  increased,  when 
compared to SHRSP. 
 
 
 
 
 
 
 
 
Figure 4.1 Weights of neonatal rats in the SHRSP, SP.WKYGla14a, WKY.SPGla14a and WKY 
A) Heart weight of neonates (measured in g).  B) Body weights of neonates (measured in 
g).  C) Ratio of heart weight to body weight in neonates. *p<0.05 
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As this suggests the weight of the heart is not changing between the strains, 
functional experiments in the neonatal heart will investigate the cellular effects 
of hypertrophy, specifically on isolated fibroblasts and cardiomyocytes, as it is 
important  to  understand  the  different  cell  types,  and  their  response  to 
stimulation and trauma.  Growth and development of the ventricle during the 
early  stages  of  foetal  and  neonatal,  depends  largely  on  3  phases  of  changes 
which occur in the cardiomyocyte population (Clubb FJ & Bishop SP. 1984).  As 
cardiomyocytes stop proliferating at around 3 5 days after birth, it is essential to 
isolate  cells  prior  to  this.    ANG  II  promotes  cardiomyocyte  hypertrophy,  and 
drives up blood pressure by initiating systemic vasoconstriction, so stimulation of 
our isolated cardiomyocytes with increasing concentrations of ANG II, and gene 
expression analysis of RNA extracted from the cells will inform as to how the 
different strains respond to this treatment.  Phalloidin staining which is designed 
to stain cells and allow for accurate sizing will be used to investigate the effects 
of ANG II stimulation on cardiomyocytes.  As cardiomyocytes are a major cause 
of remodelling in the heart, sizing of these cells in the SHRSP and WKY strains 
will  identify  if  this  is  a  possible  cause  for  the  severe  phenotype  of 
WKY.SPGla14a, and define if there is a link to hypertrophy.  The scratch assay is 
designed  to  study  cell  migration,  and  to  some  extent,  it  mimics  how  cells 
migrate,  and  react  to  tissue  trauma,  in  vivo.    Fibrosis  is  the  formation  or 
development of  excess  fibrous  connective  tissue,  normally  as  a  reparative  or 
reactive  process,  so  the  scratch  assay  should  give  an  indication  to  how  the 
different  strains  are  responding,  and  their  potential  fibrotic  build  up.    To 
confirm any differences in cell migration is due to cell migration and not to the 
cells growing, the cell proliferation assay (MTT assay) will be performed on cells 
treated in the same way as those in the scratch assay.  These techniques should 
provide  a  valuable  insight  into  the  functional  aspects  of  hypertrophy  in  the 
SHRSP, SP.WKYGla14a, WKY.SPGla14a and WKY strains. 
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4.2 Methods 
4.2.1   TotalPrep RNA Amplification 
RNA amplification for array analysis was prepared using the Illumina
® TotalPrep 
RNA  Amplification  Kit  (AMIL1791).    Before  proceeding,  RNA  was  analysed  for 
purity  to  ensure  the  RNA  was  free  of  contaminating  proteins,  DNA,  phenol 
ethanol and salts involved in the RNA isolation procedure.  Ratio of A260 to A280 
should fall in the range of 1.7 2.1.  Integrity was analysed using the Agilent
® 
2100 bioanalyzer, and ensured the RNA sample is full length, and short samples 
may produce small cDNA’s which may potentially lack a portion of the coding 
region.  The RNA Integrity Number (RIN) is calculated by analysing information 
from both the RNA bands and RNA peaks (potential degradation) and provides a 
more complete overview of the condition of the RNA.  Typically, a RIN value of 
8.0+ was deemed acceptable for further work on the sample.  Examples of the 
agilent graphs are in the appendix (Figure A.1A).  Throughout this procedure, it 
is important to use RNase free tubes, RNase free Rainin tips, pipettes which have 
been cleaned thoroughly with RNase Zap and Nuclease free water.  Incubations 
were performed using an MJ Research PTC Gradient Cycler.  RNA samples were 
diluted to 45.45ng/ l, and the concentration confirmed by nanodropping each 
sample  in  triplicate.    Reverse  transcription  mastermix  is  comprised  of  the 
following reagents to synthesize first strand cDNA:  
Reverse Transcription  vol in  l 
T7 Oligo(dT) Primer   1 
10X First strand buffer  2 
dNTP Mix      4 
RNase Inhibitor    1 
Arrayscript      1 
Diluted RNA      11 Wendy Crawford, 2010          95 
The mix was pipetted up and down 2 3 times, flicked 3 4 times, and centrifuged 
briefly to collect at the bottom of the tube.  The reaction is incubated for 2 
hours  at  42
oC,  with  the  lid  temperature  set  to  16
oC  or  the  lid  temperature 
disabled.  The reaction was placed on ice before proceeding with the Second 
strand cDNA synthesis.  Second strand cDNA synthesis master mix was prepared 
on ice as follows: 
Second Strand Synthesis  vol in  l 
Nuclease free water  63 
10X Second strand buffer  10 
dNTP Mix      4 
DNA polymerase    2 
RNase H      1 
The second strand master mix was added to the reverse transcription reaction, 
pipetted up and down 2 3 times, flicked 3 4 times, and centrifuged briefly to 
collect at the bottom of the tube.  The mix is incubated for 2 hours at 16
oC.  The 
reaction was placed on ice before proceeding with the cDNA purification.  250 l 
cDNA binding buffer was added to each sample and pipetted up and down 2 3 
times, flicked 3 4 times, and centrifuged briefly to collect at the bottom of the 
tube.  The cDNA sample/cDNA binding buffer was applied to the centre of a 
cDNA  filter  cartridge  (seated  in  a  wash  tube,  supplied  with  the  kit),  and 
centrifuged for 1 minute at 10,000g.  The flow through was discarded and the 
cDNA filter cartridge replaced in the wash tube.  500 l wash buffer (supplied 
with the kit, and adjusted to volume with 100% EtOH (Sigma 200 proof)) was 
applied to the cDNA filter cartridge and centrifuged for 1 minute at 10,000g.  
The flow through was discarded and the cDNA filter cartridge was placed in an 
elution tube.  20 l of nuclease free water (preheated to 55
oC) was applied to 
the cDNA filter cartridge, and incubated for 2 minutes at room temperature, 
then centrifuged for 1 minute at 10,000g.  The eluate was transferred to 0.5ml Wendy Crawford, 2010          96 
RNase free PCR tube.  In Vitro transcription (IVT) synthesis of cRNA master mix 
was prepared on ice as follows: 
In Vitro transcription   vol in  l 
T7 10X reaction buffer  2.5 
T7 enzyme mix    2.5 
Biotin NTP mix    2.5 
Biotin NTP is used at it biotinylates the nucleic acids, and also binds with high 
affinity to streptavidin, which in a Cy3 labelled form, is used downstream as a 
means  of  detecting  the  signal  from  the  hybridization  of  the  cRNA  to  the 
BeadChip.  The IVT master mix was added to each cDNA sample, pippetted up 
and down 2 3 times, flicked 3 4 times, and centrifuged briefly to collect at the 
bottom of the tube.  The reaction was incubated for 14 hours at 37
oC, then for 
up to 48 hours at 4
oC.  The reaction was quenched by the addition of 75 l of 
nuclease free water, and placed on ice before proceeding immediately to the 
cRNA purification step.  350 l of cRNA binding buffer and 250 l of 100% EtOH 
(Sigma 200 proof) was added to each sample, and pipetted up and down 2 3 
times.  The cRNA/100% EtOH mix was applied to a cRNA filter cartridge, and 
centrifuged for 1 minute at 10,000g.  The flow through was discarded and the 
cRNA filter cartridge replaced in the collection tube.  650 l of wash buffer was 
applied to the cRNA filter cartridge and centrifuged for 1 minute at 10,000g.  
The flow through was discarded and the cRNA filter cartridge replaced in the 
collection tube.  The cRNA filter cartridge was centrifuged for an additional 1 
minute at 10,000g to remove any traces of the wash buffer, and was placed in a 
clean collection tube.  200ul of nuclease free water (preheated to 55
oC) was 
applied to the cRNA filter cartridge, and incubated for 10 minutes at 55
oC, then 
centrifuged  for  1.5  minute  at  10,000g.    The  samples  were  assessed  by 
nanodropping and Agilent
® 2100 bioanalyzer, and had to pass stringent checks 
before proceeding to hybridization to the BeadChip.  An example of the shape of 
bell shaped curve expected is in the appendix (Figure A.1B).  The samples were 
diluted  to  150ng/ l,  and  the  concentration  confirmed  by  nanodropping  each 
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4.2.2   Hybridization to the BeadChip 
The hybridization buffer and humidity control buffer (HCB) were heated at 58
oC 
for 10 minutes to dissolve any salts, and cooled to room temperature before use.  
The BeadChip Hyb chamber apparatus was set up, and 200 l was added to each 
well, and the apparatus lid was applied and left at room temperature.  The 
BeadChips were removed from the packaging and placed on the Hyb chamber 
insert.  5 l of the diluted cRNA was added to 10 l HYB buffer, and heated for 5 
minutes  at  65
oC,  vortexed,  pulse  centrifuged  and  allowed  to  cool  to  room 
temperature.  The sample mixes were then applied to the inlet ports on the 
BeadChip, the BeadChip was loaded into the Hyb chamber, and incubated for 16 
hours at 58
oC, with rocking.  A 1X High Temp wash buffer was prepared, and 
placed in the hybex waterbath insert within the hybex heating base, which was 
set to 55
oC overnight.  The BeadChips were removed from the Hyb chamber, and 
submerged  face  up  in  a  pyrex  beaker  containing  wash  E1BC  buffer,  and  the 
coverseal  removed  carefully,  then  placed  in  a  slide  rack  in  a  wash  chamber 
containing wash E1BC buffer.  The slide rack was placed in the hybex waterbath, 
and the BeadChips were incubated for 10 minutes at 55
oC.  The slide rack was 
removed, and placed in the wash chamber containing wash E1BC buffer used 
previously, and plunged in and out of the buffer 5 to 10 times, then placed on an 
orbital shaker for 5 minutes at room temperature.  The rack was removed and 
placed in a staining chamber containing 250ml 100% EtOH (Sigma 200 proof) and 
plunged in and out of the buffer 5 to 10 times, then placed on an orbital shaker 
for 10 minutes at room temperature.  The rack was removed and placed in a 
staining chamber containing 250ml of fresh wash E1BC buffer and plunged in and 
out of the buffer 5 to 10 times, then placed on an orbital shaker for 2 minutes at 
room temperature.  4ml of Block E1 buffer was added to individual wash trays, 
and the BeadChip was placed in it, face up, using tweezers, then the wash tray 
was  placed  on  an  orbital  shaker  for  10  minutes  at  room  temperature.  
Streptavidin Cy3 was diluted to 1:1000 with Block E1 buffer, and placed in a 
clean  individual  wash  tray.    Streptavidin Cy3  acts  as  secondary  agent  to  the 
biotinylated  cRNA  hybridized  to  the  BeadChip,  and  is  used  to  detect  the 
intensity of this signal.  The BeadChip was transferred to the wash tray and then 
this was placed on an orbital shaker for 10 minutes at room temperature.  The 
BeadChip  was  transferred  to  a  slide  rack  placed  in  a  clean  staining  dish 
containing 250ml fresh wash E1BC buffer, and plunged in and out of the buffer 5 Wendy Crawford, 2010          98 
times, then placed on an orbital shaker for 5 minutes at room temperature.  The 
BeadChip was then dried by placing the slide rack on clean paper towels, and 
placing  in  plate  holder,  and  centrifuging  at  275  g  for  4  minutes  at  room 
temperature.    The  dried  BeadChips  are  then  transferred  to  the  Illumina 
BeadArray Reader to scan, and the output data is visualised using Beadstudio 
software. 
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4.3 Results 
4.3.1   Illumina Microarray of neonatal, 5 week and 16 week hearts 
of SHRSP, WKY and chromosome 14a congenic strains. 
The Illumina microarray and Partek analysis was carried out using RNA extracted 
from the same 5 & 16 week of age rats previously used in the Affymetrix exon 
array  from the  hearts  of  the chromosome  14a  congenic  strain animals,  along 
with the parental SHRSP and WKY strains (Results Chapter 3).  Neonatal hearts of 
the  same  strains  were  subjected  to  the  same  handling  and  RNA  extraction 
conditions as the previous samples.  The neonatal, 5 & 16 week of age time 
points  investigate  the  potential  for  differential  gene  expression,  with  the 
progression of disease, and allow identification of genes which may be expressed 
prior to the onset of disease, thus having a causative effect.  The data for each 
strain was filtered in a venn diagram and the resulting area of intersect for the 
four strains indicate genes which are common (Figure 4.2).  The results of the 
neonatal microarray indicate 4 significantly differentially expressed positional 
genes.  These are Osteopontin (Spp1), Hydroxysteroid (17 beta) dehydrogenase 
13 (Hsd17b13), Zinc finger protein (Zfp644), which are all located within the 
congenic  region  of  chromosome  14a  strains,  and  Ras related  associated  with 
diabetes  (Rrad)  which  is  located  on  chromosome  19.    Spp1’s  expression  in 
cardiomyocytes  coincides  with  heart  failure  development  from  hypertrophy 
(Singh  K  et  al.  1999).    This  is  of  particular  interest  as  Spp1  has  also  been 
implicated to an increase in LVMI, a precursor to LVH, which is a phenotypic 
characteristic of the SHRSP and WKY.SPGla14a congenic strain.  Signal intensities 
of each probe implicated in the microarray has been analysed across the 3 time 
points used.  The results show that Spp1 expression is showing greater variability 
in the neonates (Figure 4.3).  The increased signal intensity in SHRSP relative to 
SP.WKYGla14a, and increased signal intensity in WKY.SPGla14a relative to WKY 
is a similar profile to that of the LVMI measurements, which is interesting as it 
would suggest that there may be a link between the phenotypic data and the 
Spp1 expression.  The Spp1 signal appears to have decreased at 5 weeks of age, 
with no difference in signal intensity.  The other genes identified appear to have 
no apparent links to LVH, and while still of interest, will not be focussed on in 
this project. Wendy Crawford, 2010          100 
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Figure  4.2  Microarray  analysis  of  the  A)  neonatal,  B)  5  week  and  C)  16  week  SHRSP,  WKY, 
SP.WKYGla14a and WKY.SPGla14a strains.  
Venn diagrams illustrating microarray results of gene expression profiles in the heart of 
rats. The number of probes significantly differently expressed for each time point in each 
pair wise comparison are shown in the areas of intersect on the venn diagrams.   
Table 4.1 Genes which have been implicated in the microarray, across the time points 
Genes are shown which have been implicated by the microarray at each time point, and 
their chromosome position has been identified.  
Time point  Gene  Chromosome locus 
Osteopontin   14: 6,422,741 6,426,400 
Hydroxysteroid (17 beta) 
dehydrogenase 13  
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Zinc finger protein   14: 3,645,610 3,720,694 
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chemokine  (C X C  motif) 
ligand 13  
14: 15,126,337 15,131,368 
Hydroxysteroid (17 beta) 
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Principal  component  analysis  (PCA)  is  a  mathematical  procedure  which  can 
transform a number of closely related variables into a number of uncorrelated 
variables  called  principal  components,  which  are  still  related  to  the  original 
variables.  This transformation is handled so that the first principal component 
has as high a variance as possible (to account for as much of the variability in 
the data as possible).  Each component which follows has the highest variance 
possible  with  the  condition  that  it  must  be  orthogonal  to  the  previous 
components (Jolliffe IT. 2002).  This is then taken into account when we build 
the ANOVA model.  The experimental samples were randomised across 4 array 
chips, and introduce another aspect to the variables which can be accounted for 
with the PCA analysis.  The PCA mapping shows that there is a minor chip bias 
(Figure 4.3A), which is confirmed by PCA mapping of the sample groups, as this 
shows grouping of the each strain at each time point, which is to be expected 
(Figure  4.3B).    The  PCA  plot  allows  for  an  assessment  to  be  made  of  the 
experimental and technical aspects of the array. 
The signal intensities of the microarray probes of the neonatal targets (Spp1, 
Hsd17b13,  Rrad  &  Zfp644)  were  plotted  to  identify  differences  between  the 
strains, and to confirm which targets should be prioritised for further analysis.  
The intensity profile of Spp1’s mirrors the profile of the LVMI data previously 
generated,  and  the  signal  intensity  profiles  of  the  other  neonatal  targets 
(Hsd17b13, Rrad & Zfp644) are shown (Figure 4.4 B, C & D).  The initial analysis 
will be validation of the microarray by gene expression studies. 
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Figure 4. 3  Principal component analysis mapping of the Illumina microarray data 
A) Overlaying the PCA plot with the sentrix barcode indicates a bias has occurred in the 
microarray experiment.  This means a sample may show a bias, depending on the chip it is 
hybridized to.  B) Overlaying the PCA plot with the sample group data confirms the bias 
caused by chip location of each sample. 
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Figure 4.4 Microarray signal intensities of target genes in  neonatal, 5 week and  16 week SHRSP, 
SP.WKYGla14a, (F) WKY.SPGla14a (D) and WKY strains. 
The graphs show the microarray signal intensities of the genes identified in neonatal hearts.  
The intensities have been shown at the 5 week and 16 week time point.  A) Spp1.  B) 
Hsd17b13.  C) Rrad.  D)  Zfp644.  n-4 *p<0.05 
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4.3.2   Validation of microarray targets by qRT-PCR in neonatal 
hearts 
Validation  of  the  Illumina  microarray  gene  targets  focussed  mainly  on  the 
neonatal  time  point.    The  5  &  16  week  of  age  gene  expression  was  also 
performed to validate the signal intensity profiles (Figure 4.4). Spp1 has been 
validated  through  the  use  of  2  probes  (labelled  Rn00681031_m1  & 
Rn00563571_m1) sitting on different exon boundaries, with both giving similar 
results.    In  the  neonatal  hearts,  gene  expression  levels  identified  by  the 
microarray  validate  the  signal  intensity  (Figure  4.5A).    Arhgap24  was  also 
included in the validation, as it has been implicated at the 16 week time point, 
and it is also located on chromosome 14, within the congenic region.  It is also 
shown to have a difference in expression in the analysis of the 5 week WKY 
compared with WKY.SPGla14a.  Due to technical problems which occurred with 
the samples, validation of the 5 week data is incomplete.  Spp1 was the only 
gene to be investigated at the 5 week of age time point and large error bars are 
present (Figure 4.5B).  The 16 week data has also proved problematic to validate 
(Figure 4.5C).  Large error bars are seen on both the 5 week and 16 week gene 
expression graphs (Figure 4.5B & C) which was due to technical and biological 
issues with the housekeeping gene (GapDH).  Zfp644 was not analysed during 
these experiments as a suitable Taqman probe was not available at the time.  
Comparisons were analysed using the student’s pair wise t test.   
The qRT PCR results confirm the findings of the neonatal signal intensity analysis 
of the microarray data of Spp1 (Figure 4.4A).  The gene expression profiles of 
the  other  target  genes  confirm  the  signal  intensities  in  the  neonatal  hearts 
(Figure 4.4 B, C &D) and follow the origin of the Chromosome 14a strains, and 
this supports the hypothesis that one or more of these genes may contribute to 
the  hypertrophic  phenotype.    Further  investigation  of  the  Spp1  gene  was 
prioritised as it was the top hit from the microarray.  This will be carried out 
through sequencing, both of the coding region and the regulatory regions.  This 
will  illustrate  any  SNPs  which  may  be  contributing  to  the  change  in  gene 
expression of Spp1, in the comparison between the chromosome 14a congenic 
strains and the parental strains.  
 Wendy Crawford, 2010          105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.5  Validation  of  microarray  with  mRNA  expression  in  SHRSP,  SP.WKYGla14a, 
WKY.SPGla14a and WKY at the A) neonatal, B) 5 week and C) 16 week time points in the heart 
Expression is shown as an RQ value of SHRSP. A) Neonatal expression of microarray 
probes B) 5 week Spp1 expression.  C) 16 week expression of microarray probes. n-4 
*p<0.05. 
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4.3.3   Spp1 Primer design and sequencing 
Primers were designed to cover the ORF of the Spp1 gene, PCR was carried out, 
and  the  amplified  products  were  sequenced  and  aligned  to  Brown  Norway 
sequence  using  Seqscape  v2.1.    The  5’  upstream  region  of  Spp1  is  not  well 
annotated,  so  to  facilitate  the  primer  design  and  subsequent  sequencing,  an 
alignment was carried out of 7 common mammals, and primers were designed to 
the conserved areas of sequence.  The mus musculus strain was chosen as the 
focus  for  the  design,  as  it  shares  the  greatest  homology  with  the  rat.    The 
primers were chosen carefully, locating areas of greatest homology (Figure 4.7).  
The  section  of  sequence  shown  represents  a  small  part  of  the  alignment 
generated.  A single reverse primer was designed which was rooted in the first 
exon of the ORF, to ensure the products amplified were in the upstream region 
of Spp1.  The sequence generated was then used to design further primers to 
ensure full coverage of the upstream region of the Spp1 gene.  The PCR products 
were then cloned and transformed into a strataclone blunt ended vector, and 
positive inserts were chosen by blue/white colour selection.  The DNA from the 
cloned  products  was  checked  by  PCR  and  sequencing  to  confirm  the  correct 
insertion  and  orientation  had  been  achieved.    This  alignment  was  useful  in 
identifying conserved nucleotides (Figure 4.7).  Despite the alignment, a number 
of  primer  designs  had  to  be  implemented  to  successfully  amplify  the  Spp1 
upstream region in the SHRSP and WKY.  The primer locations for the ORF and 5’ 
upstream region are shown (Figure 4.6).  SNPs found in the 5’ promoter and ORF 
are shown (Table 4.2), and the SNP causing the amino acid change is illustrated 
in a screenshot of the Seqscape analysis (Figure 4.8). 
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Figure 4.6 Schematic of Spp1 open reading frame and proposed 5’ promoter region 
The primer positions are marked onto the schematic drawing to show their location.  The 
reverse primer for the alignment of 7 different species upstream region of Spp1shows the 
reverse primer has been rooted in the first exon of the open reading frame. 
 
Figure 4.7 Alignment of the 7 eutherian mammals, to generate primers to sequence unknown Spp1 
promoter region in Rat. 
2000 base pairs from 7 mammals of the 5’ upstream region of Spp1 were aligned using 
CLC software.  Each base is represented by a different colour.  The coloured dots are used 
to indicate a base which is conserved from the mouse to the other strains.  A difference in 
base is annotated by the appropriate letter in place of a dot to indicate the base has not been 
conserved in that location between the mouse and other mammals.  The conservation bar 
chart beneath the alignment represents the amount of homology between the mammals. 
The alignment shows the conserved regions between the 7 mammalian strains which were 
used for the primer design.  The arrows labelled AF and BF are 2 of the primers designed 
to cover the region.  The primer design followed standard rules, i.e. ~50% GC content, and 
avoiding a poly A tail. 
AF 
BF 
Spp1 gene
3’ promoter region-upstream
AF BF CF DF AF BF CF DF EF
Open reading frame
AR AR BR CR DR ER
Spp1 gene
3’ promoter region-upstream
AF BF CF DF AF BF CF DF EF
Open reading frame
AR AR BR CR DR ERWendy Crawford, 2010          108 
Table 4.2 Positions of SNPs in the upstream region and ORF of Spp1 
The positioning of the SNPs identified in the 5’ upstream region and the ORF of the Spp1 
gene, and the differences when comparing the sequence derived from the PCR products 
with that of the Brown Norway.  It also indicates if any amino acid changes have occurred 
as a result of the SNP.   
 
 
 
 
 
 
 
 
 
 
Figure 4.8 SNP found in Spp1 open reading frame 
A screenshot of the Seqscape v2.1 analysis of Spp1 open reading frame, showing the +559 
(from ATG) SNP (A→C), which causes a change in amino acid (WKY-I →SHRSP-L). 
 
Position from 
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+559  A  C  A  Yes:Isoleucine 
 >Leucine 
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4.3.4   Functional experiments of hypertrophy 
In  this  section,  functional  experiments  have  been  applied  to  heart 
cardiomyocytes and fibroblasts isolated from neonatal hearts from the SHRSP, 
SP.WKYGla14a, WKY.SPGla14a and WKY strains.  Expression of the Spp1 gene is 
analysed in cardiomyocytes and fibroblasts of the parental strains.  The qRT PCR 
results  confirm  Spp1  gene  expression  is  significantly  higher  in  SHRSP 
cardiomyocytes,  when  expressed  relative  to  SHRSP  fibroblasts  (Figure  4.9).  
Expression of Spp1 is assessed in neonatal cardiomyocytes in the SHRSP, WKY 
and  chromosome  14a  congenic  strains,  which  have  been  stimulated  with 
increasing  concentrations  of  ANG  II.    ANG  II  promotes  cardiomyocyte 
hypertrophy,  and  drives  up  blood  pressure  by  initiating  systemic 
vasoconstriction,  so  it  is  expected  that  an  increase  in  Spp1  expression  in 
cardiomyocyte  cells  will  be  detected,  with  increasing  ANG  II  concentrations.  
Spp1  expression  in  SHRSP  cardiomyocytes  was  unable  to  be  determined,  as 
expression levels of the housekeeping gene GapDH were extremely low for these 
samples,  meaning  a  full  analysis  of  this  strain  could  not  be  completed.  
Expression  of  Spp1  in  the  WKY  and  WKY.SPGla14a,  with  increasing 
concentrations of ANG II is not significantly different.  Spp1 expression in ANG II 
stimulated SP.WKYGla14a cardiomyocytes is found to be significantly higher with 
the 150nM and 200nM concentration, when compared to the WKY control (Figure 
4.10E).  Phalloidin staining was performed on SHRSP and WKY cardiomyocytes 
(an example of which is seen in Figure 4.10D) which have been stimulated with 
increasing concentrations of ANG II (0, 50nM, 100nM, 150nM and 200nM).  This 
assay is designed to stain cells and allow for accurate sizing.  Cardiomyocytes 
are a major cause of remodelling in the heart, so sizing of these cells in the 
SHRSP and WKY strains will identify if this is a possible cause for the extreme 
phenotype, and a link to hypertrophy.  The results show that when stimulated 
with ANG II, SHRSP cardiomyocytes significantly increase in size (Figure 4.10A).  
WKY cardiomyocytes stimulated with ANG II show an increase in cell size from 
the addition of 100nM upwards (Figure 4.10B).  When the cardiomyocytes sizes 
are compared between SHRSP and WKY, WKY cells are significantly larger than 
those of SHRSP at all concentrations of ANG II, including in the the non ANG II 
stimulated control (Figure 4.10C).  This does not suggest that the increase in 
WKY cells is due to hypertrophy, but rather that this occurs naturally. Wendy Crawford, 2010          110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Spp1 expression in the SHRSP and WKY cardiomyocytes and fibroblasts 
qRT-PCR measured by Taqman in neonatal rat heart cells relative to GapdH and calibrated 
to expression in the SHRSP fibroblasts, n-3.  * p<0.05 
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Figure  4.10  Cell  sizing  of  SHRSP  and  WKY  cardiomyocytes,  and  Spp1  expression  in  ANG  II 
stimulated SP.WKYGla14a, WKY.SPGla14a and WKY cardiomyocytes 
A)  ANG  II  stimulation  of  SHRSP  cardiomyocytes,  of  all  concentrations,  significantly 
increases the size of the cell.  B) ANG II stimulation of WKY cardiomyocytes, of 100nM, 
150nm,  and  200Nm  concentration,  significantly  increases  the  size  of  the  cell.                    
C) Comparing the cell size of SHRSP and WKY, there is a significant increase in size of 
WKY. All sizes were measured in microns D) Some examples of Phalloidin staining in 
cardiomyocytes. E) Spp1 expression in ANG II stimulated cardiomyocytes. A, B&C n-3 E 
n-1 * p<0.05.   
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The scratch assay is designed to study cell migration, and to some extent, it 
mimics  how  cells  migrate,  and  react  to  tissue  trauma,  in  vivo.    As  the 
WKY.SPGla14a strain has previously shown with the phenotypic results that it has 
high levels of fibrosis, this experiment compared it with the WKY strain, and the 
assay  was  carried  out  on  the  fibroblast  cells.    Comparing  the  percentage 
decrease in wound width, between the WKY and WKY.SPGla14a, at increasing 
concentrations  of  serum  in  the  media,  both  strains  show  similar  levels  of 
recovery,  with  the  peak  migration  with  10%  serum.    Both  strains  show  an 
increase in percentage (Figure 4.11).  However, if the actual distance migrated 
is  taken  into  account  the  WKY.SPGla14a  strain  migrates  further,  at  all 
concentrations, again with the peak migration at 10% serum (Table 4.3).  To 
confirm that these effects are due to migration, and not to cell proliferation, an 
MTT  assay  is  performed.    Fibroblasts  from  WKY  and  WKY.SPGla14a  were 
subjected to the same conditions of quiescence and serum added back to the 
media, as the scratch assay, and the levels of proliferation were measured.  The 
rate of proliferation in WKY fibroblasts is not increasing with the increased levels 
of serum in the media.  Although the WKY.SPGla14a fibroblasts are showing a 
pattern of increased proliferation with increased levels of serum in the media, it 
is only with the addition of 20% serum that a significantly different result is 
achieved (Figure 4.12).    
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Figure 4.11 Scratch assay, showing percentage distance migrated following the scratch trauma, with 
increasing concentrations of serum in the media, on WKY and WKY.SPGla14a fibroblasts 
A) WKY fibroblasts migration with increasing concentrations of serum in the media, over 
time.  B) WKY.SPGla14a fibroblasts migration with increasing concentrations of serum in 
the media, over time.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 MTT assay of WKY and WKY.SPGla14a congenic (D) with increasing serum in the media 
The graph shows rates of proliferation of the WKY fibroblasts are not increasing with the 
increased levels of serum in the media.  WKY.SPGla14a fibroblasts show a pattern of 
increasing proliferation. n-1 * p<0.05 
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Table 4.3 Scratch assay, showing actual distance migrated, on WKY and WKY.SPGla14a fibroblasts 
The measurements of actual distance moved following the scratch trauma are shown. 
 
Strain  Time  diff in 
microns 
1%  5%  10%  20% 
0 hr  0  0  0  0  0 
16hr   29.68   55.99   126.47   62.64   150.76  
WKY 
24hr   18.61   77.93   142.70   131.66   188.15 
0hr  0  0  0  0  0 
16hr   34.26    110.38   238.52   189.65   132.04 
WKY.SPGla14a 
24hr   42.84  134.86   299.05   305.44  201.43 Wendy Crawford, 2010          115 
4.4 Discussion 
The  experiments  in  this  chapter  were  designed  to  validate  and  functionally 
follow up the results of the Illumina microarray.  Particular emphasis was placed 
on the neonatal time point as it had been shown from previous phenotypic data 
generated within this laboratory, that hypertrophy is initiated before 5 weeks of 
age, prior to the onset of hypertension.  Expression profiles compared across all 
4 strains identified 4 positional candidate genes.  Validation by gene expression 
confirmed  Spp1  as  a  positional  candidate  gene,  and  on  this  basis,  was 
investigated through a series of experiments, including sequencing of the open 
reading frame and 3’ upstream promoter region.  Spp1 was prioritised for further 
analysis due the signal intensity profile which mirrors the profile of LVMI data 
across the 4 strains.  Spp1 is an acidic phosphoprotein adhesion molecule, which 
is produced by mineralized tissue cells, epithelial cells, and activated immune 
system cells.  It has cytokine like, chemotactic and pro adhesive properties, and 
is  expressed  by  infiltrating  macrophages  during  wound  healing,  and  has  also 
been implicated in wound repair in the heart (Murry CE et al. 1994). It has been 
identified in vasculature, where it contributes to vascular smooth muscle cell re 
modelling functions in response to endothelial cell damage (Ashizawa N et al. 
1996).  Spp1 synthesis is stimulated by calcitrol (1,25 dihydroxy vitamin D3), and 
is produced by a variety of tissue types including fibroblasts, osteoblasts, some 
bone marrow cells, hypertrophic chondrocytes, endothelial cells, and non bone 
cells in the inner ear, brain, kidney, and placenta.  Regulation of the Spp1 gene 
depends on the cell type expressing it.  In the bone, Runx2 and Osterix (Osx) are 
transcription  factors  needed  for  Spp1  expression  (Nakashima  K  et  al.  2002).  
Runx2 and Osx bind promoters of osteoblast specific genes such as Col1α1, Bsp, 
and Spp1 and upregulate transcription (Ducy P et al. 1997).  Hypocalcaemia and 
hypophosphataemia are events which stimulate the kidney proximal tubule cells 
to produce calcitrol, which lead to an increase in Spp1 transcription, translation 
and secretion (Yucha C & Guthrie D. 2003).  This is due to the presence of a 
specific vitamin D response element (VDRE) in the Spp1 gene promoter.  Spp1 
expression  is  also  stimulated  upon  exposure  of  cells  to  pro inflammatory 
cytokines, which are mediators of acute inflammation (tumour necrosis factor α 
[TNFα], infterleukin 1β [IL 1β]), ANG II, TGFβ and parathyroid hormone (PTH).  Wendy Crawford, 2010          116 
Hyperglycaemia and hypoxia are also known to increase Spp1 expression (Sodhi 
CP et al. 2001). 
Functional experiments of hypertrophy identified over expression of Spp1 in the 
SHRSP primary cardiomyocytes, which supports the potential for its role in this 
condition.    Transgenic  mice  generated  to  specifically  over express  Spp1  in 
cardiomyocytes showed a high degree of lethality, with most dying 10 15 weeks 
after  birth.    Spp1  expression  is  inhibited  by  Dox,  an  inhibitor  of  matrix 
metalloproteases which can also attenuate cardiac hypertrophy in mice (Errami 
M et al. 2008).  It is only upon administration of Dox at 5 weeks of age, that 
survival of these mice increased to that of the control mice (Renault MA et al. 
2010).  This supports Spp1’s role not only as an inducer of myocarditis, but also 
maintains the severity of the process.  Spp1 has also previously been identified 
in rat cardiac fibroblasts, where it contributes to ANG II induced re modelling.  
Interleukin 18 stimulates an increase in expression of Spp1 in fibroblasts, which 
leads to diastolic dysfunction and cardiac fibrosis in mouse models (Yu Q et al. 
2009).  Knock out mice lacking the Spp1 gene have characteristic features, of 
reduced fibrosis in response to cardiac injury, increased ventricular dilation and 
systolic dysfunction.  This deficiency in fibroblast formation is linked to decease 
in remodelling via matrix metalloproteases (MMPs).   Studies have shown that 
Spp1 is cleaved by at least 2 classes of proteases:
 thrombin and MMPs (Scatena M 
et al. 2007).  Furthermore, Spp1 conditional transgenic mice have shown that a 
decrease  in  Spp1  expression  reduces  fatality,  but  interstitial  fibrosis  is 
maintained (Renault MA et al. 2010).  It has also been identified in cultured 
cardiomyocytes, where its expression is associated with LVH (Graf K et al. 1997).  
Cardiac  re modelling  is  a  key  element  in  LV  dysfunction  and  can  affect  the 
clinical course of heart failure. The hallmarks of re modelling are cardiomyocyte 
hypertrophy,  extracellular  matrix  deposition  (ECM)  and  fibrosis,  and  can  also 
include a change in expression of many cardiac genes.  Activated fibroblasts or 
myofibroblasts are the source of ECM proteins in scar formation, and may serve 
as a matrix for cell colonization during tissue regeneration (Lenga Y et al. 2008). 
Spp1  plasma  levels  and  Spp1 expressing  CD4+  lymphocytes correlate  with  the 
severity of heart failure, which suggests that mechanisms in heart failure are 
associated with Spp1 expression, and also plasma levels may be used as clinical 
marker (Francia P et al. 2010).   Wendy Crawford, 2010          117 
DNA  sequencing  was  undertaken  of  the  upstream  regulatory  region,  however 
primer design within this region was problematic due to the number of repetitive 
elements present.  As the Brown Norway sequence is also poorly annotated, an 
alignment was made around the promoter regions of mouse and human to detect 
areas of homology.  From the subsequent PCR products, SNP’s were identified in 
the  upstream  region  of  Spp1.    Transcriptional  repression  is  one  of  the 
mechanisms  by  which  the  precise  control  of  gene  expression  is  regulated, 
however, sequencing is still ongoing, following which Transfac analysis of this 
region will take place.  To date, a single SNP in the ORF causing a change in 
amino acid (isoleucine to leucine) has been identified in the SHRSP strain (Table 
4.2).  This amino acid region was aligned with mouse and human, it was found 
that it was not conserved across the species, which suggests that this is unlikely 
to affect gene function.  This is supported by the presence of a Leucine residue 
in the same position in the mouse (Figure 4.13).  In addition, to confirm the 
presence  of the  SNP,  sequencing  will  be  undertaken  of  the  Chromosome  14a 
congenic strains.  
 
 
 
 
 
Figure 4.13 Spp1 amino acid alignment in the rat, mouse and human. 
The alignment shows the amino acid in rat WKY (I) is not conserved across the species.  
Also the change to Leucine (L) in the SHRSP is conserved in the mouse. 
Primary  cardiomyocyte  and  fibroblast  cells  from  neonatal  rats  of  the  SHRSP, 
WKY and the congenic strains were isolated to allow for further analysis into the 
functional effects of hypertrophy.  Expression levels of Spp1 were investigated in 
the SHRSP and WKY parental strains in the cardiomyocytes and fibroblasts, and it 
was shown that Spp1 expression is significantly higher in SHRSP cardiomyocytes, 
and  WKY  fibroblasts  (Figure  4.5A).    Increasing  concentrations  of  ANG  II 
stimulation of the cardiomyocytes showed that this had no effect in changing the 
levels of Spp1 expression in the WKY and WKY.SPGla14a strains.  A significant 
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change  was  detected  in  Spp1  gene  expression  at  150nM  and  200nM 
concentrations of ANG II stimulation in the SP.WKYGla14a, when compared with 
WKY control (Figure 4.5B).  Spp1 gene expression in the SHRSP has not been 
reported  due  to  failure  of  GapdH  amplification.    Cell  sizing  of  the 
cardiomyocytes indicates that WKY cells are significantly larger than SHRSP, and 
ANG II stimulation, although increasing the size does not change the difference 
seen between the strains (Figure 4.7).  Stimulation of the SP.WKYGla14a and 
WKY.SPGla14a strains with ANG II, and subsequent analysis of Spp1 expression 
should  also  take  place  to  confirm  the  development  of  hypertrophy.    As 
WKY.SPGla14a  was  identified  as  having  an  extreme  phenotype  of  fibrosis, 
independent of BP, investigation of this strain, comparing with the WKY parental 
was  focussed  on  for subsequent  experiments.    The  scratch assay  showed  the 
WKY.SPGla14a  fibroblasts  migrated  further  following  the  scratch  trauma, 
compared with WKY.  This supports the hypothesis that the WKY.SPGla14a strain 
is involved in fibrosis.  The MTT assay was performed to confirm the migration 
found  in  the  scratch  assay  is  due  to  the  addition  of  serum,  and  not  due  to 
proliferation of the cells.  WKY.SPGla14a fibroblast proliferation was found to be 
significantly higher with 20% serum in the media, but when this is compared with 
the  scratch  assay  findings  with  the  same  concentration,  it  is  found  to  have 
decreased  cell  migration  (Table  4.3).    This  then  suggests  that  the  migration 
achieved in the scratch assay is due to the increased levels of serum added to 
the media, and not due to cell proliferation.  This is to be expected as serum is 
known  to  be  required  for  cell  growth  and  survival.    Significant  myocardial 
inflammation develops in ANG II hypertension, which is responsive to aldosterone 
blockade (Rocha et al. 2002).  ANG II is a critical factor in cardiac re modelling 
which  involves  hypertrophy,  fibroblast  proliferation,  and  extracellular  matrix 
production.    Spp1  inhibits  ANG  II  induced  inflammation  and  iNOS,  a  factor 
involved in cell injury after ischaemia reperfusion.  It would be of interest to 
test  this  in  vitro,  so  further  investigations  will  include  Spp1  knock  out  using 
siRNA transfection techniques.  The effects of this can be tested using Taqman 
qRT PCR  gene  expression  analysis,  specifically  with  Col1a1,  matrix 
metalloprotease  2  (MMP2)  and  matrix  metalloprotease  9  (MMP9),  which  will 
identify if the stimulation is having an effect on collagen production in the cells.  
Other genes to be investigated by Taqman qRT PCR gene expression analysis in 
the ANG II stimulated cardiomyocytes include Col1a1, MMP2 and MMP9.  Brain Wendy Crawford, 2010          119 
natriuretic  peptide  (BNP)  is  released  from  the  ventricles  in  response  to 
stretching of the cardiomyocytes and is considered to be a superior marker of 
overload LV dysfunction (Birner CM et al. 2007).  Atrial natriuretic peptide (ANP) 
is a powerful vasodilator released from the atria in response to high BP to reduce 
it.  This would especially be of interest as ANG II suppresses ANP secretion via 
the AT1 receptor (Oh YB et al. 2010).   
It should be noted that the other genes identified at the neonatal time point, 
and  validated  through  Taqman  qRT PCR  gene  expression  analysis  will  be 
investigated further.  Spp1 was prioritised for further investigation, and was the 
focus  of  this  investigation  as  its  signal  intensity  profile  from  the  microarray 
mirrored the profile of LVMI and therefore represents an excellent positional 
candidate gene for LVMI in the SHRSP.    
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The experiments performed in this project applied a wide range of functional 
genomic techniques in the investigation of hypertrophy in the SHRSP.  The exon 
array and Illumina microarray techniques have provided valuable chromosome 14 
gene candidates in this field.  The hypertrophy candidate gene Spp1 has been 
examined through expression profiling from the Illumina microarray, ORF and 
promoter  sequence  analysis,  and  functional  studies  utilising  primary  cells 
isolated from neonatal hearts.  The functional studies were designed to examine 
the  expression  and  response  of  Spp1,  following  ANG  II  stimulation  in  the 
cardiomyocytes,  and  how  the  cells  reacted  following  tissue  trauma  in  the 
fibroblasts.  These techniques have provided an excellent springboard for future 
experiments relating to Spp1, and its role as a functional positional candidate of 
LVH.  The scratch assay has provided valuable information on how the fibroblasts 
in the WKY.SPGla14a strain migrate after the scratch to re establish cell cell 
contact, and this contributes to fibrosis.  It also provides us with information on 
how the ECM helps to form cell interactions.  To fully understand the role of the 
fibroblasts, and how they are reacting to form the cell cell contact, the media 
from the cells should be removed and analysed.  Collagen assay performed on 
this media will indicate the levels of collagen being released in response to the 
trauma.  This will also help us to understand collagen’s role in fibrosis.  The cells 
should  be  removed  for  gene  expression  analysis.    Again,  this  will  help  our 
understanding of the genes involved, and their role in the functional pathway of 
Spp1.  Further work in Spp1 would include a knockdown transfection of primary 
fibroblasts using siRNA technology.  RNA will be extracted from the transfected 
fibroblast  cells  and  analysed  for  Spp1  gene  expression  to  confirm  the 
transfection.    To  further  confirm  the  pathways  of  hypertrophy,  analysis  of 
related genes, such as Col1a1 and MMP2 should also be analysed, as this will 
provide valuable information about how the cells are responding to the knock 
out  of  Spp1.    BNP  and  ANP  will  also  be  measured,  as  this  will  helping  the 
development of the functional pathways which Spp1 is involved in.  The role of 
BNP and ANP’s involvement in Spp1’s expression requires further work studies, 
as they are markers of hypertrophy, and will confirm at the neonatal time point, 
Spp1’s role as a causative gene in LVH. 
The knock out mice model of Spp1 has previously identified its role in LVH, as 
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induced cardiac injury.  They have also shown an increase in ventricular dilation 
and  systolic  dysfunction,  confirming  Spp1’s  role  in  cardiac  remodelling 
(Trueblood NA et al. 2001).  A trend in reduced apoptosis has been noted, which 
confirms a function of Spp1 of being an antiapoptotic, which supports the theory 
that Spp1 induces the protective mechanism of wound healing after myocardial 
injury (Chandrashekhar Y et al. 2004).  The ideal next step from this data would 
be to generate a Spp1 knock out in the WKY.SPGla14a congenic strain, and to 
analyse the effect on phenotype.  Real time PCR can be carried out on various 
genes including Spp1, Col1a1 and MMP2 will be carried out, and this should lead 
towards building a pathway and potential mechanism for the functional role of 
Spp1.  
Promoter studies will be undertaken to evaluate the potential functional effects 
of  the  SNP’s  in  the  upstream  region  of  Spp1.    Similar  experiments  will  be 
undertaken for the Cxcl13 promoter, as it has a SNP in a potential transcription 
factor binding site.  Transcriptional repressor proteins can associate with their 
target  genes  either  directly  through  a  DNA binding  domain  or  indirectly  by 
interacting  with  other  DNA bound  proteins.  A  repressor  protein  can  inhibit 
transcription  selectively,  by  masking  a  transcriptional  activation  domain, 
blocking interaction of an activator with other components of the transcription 
machinery, or by displacing an activator from the DNA.  DNA response elements 
can exert allosteric effects on transcriptional regulators, such that regulators 
may activate transcription in the context of one gene, yet repress transcription 
in another. 
Western blot analysis will be undertaken with protein extracted from SHRSP, 
WKY, SP.WKYGla14a and WKY.SPGla14a hearts, at neonatal, 5 week of age and 
16 week of age time points.  This will ascertain the potential functional change 
the SNP in the ORF of Spp1, due to the change in the amino acid.   
Cxcl13 does display differential expression in chromosome 14a congenic strains.  
Although Cxcl13 does not have any obvious links to hypertrophy, this does not 
discount  the  information  gathered  from  the  exon  array.    The  SNP  in  the  5’ 
promoter region of Cxcl13 resulted in the loss of the HNF4 transcription factor 
loss the WKY strain.  The 3’UTR SNP should also be investigated further.  The 3’ 
region  is  a  common  area  for  microRNA’s,  and  a  SNP  in  this  region  could  be Wendy Crawford, 2010          123 
suggestive  of  miR  control  of  the  expression  of  the  gene.    The  area  will  be 
scanned, and any miRs in the region of the SNP will be investigated through 
normal expression techniques.  Post transcriptional work will also be carried out 
to see if the change found in the exon array may be related to Cxcl13’s protein.  
Western blot analysis will indicate if there are differing levels of Cxcl13 protein 
in the heart tissue, when comparing the parental strains of SHRSP and WKY and 
the congenic strains of SP.WKYGla14a and WKY.SPGla14a.   
The  Clock  gene  has  been  fully  investigated  for  potential  alternate  splicing 
suggested by the exon array and the signal intensity plots.  The SNP’s found have 
been  verified  through  probe  alignment  to  the  sequence  and  confirmed  that 
alternative splicing is not occurring in Clock.  The probes for exon 5 did not align 
with the +432 SNP, which has previously been identified and is illustrated on the 
ensemble page for the Clock gene.  The probes for exon 9 aligned with the +816 
SNP and this confirms the change in signal intensity, as the probes would not 
have hybridized to this region.  This SNP has not been identified previously, and 
should be investigated further. 
Hsd17b13, Rrad and Zfp644 were identified by the neonatal Ilumina microarray 
as being potential positional candidates for hypertrophy.  As Rrad is positioned 
on chromosome 19, this would suggest that it is having a trans effect on the 
chromosome  14a  congenic  strains.    Hsd17b13  and  Zfp644  are  located  on 
chromosome 14.  These microarray targets will be investigated further, as the 
neonatal gene expression analysis confirmed the findings of the array.   
The results of the 5 week heart exon analysis filtered on the minimal congenic 
region (29Mbp) and the results of the Illumina genome wide analysis from the 
same animals compared well.  There were additional positional candidate genes 
on  chromosome  14,  however,  the  additional  time  points  in  the  Illumina 
experiments proved vital in the identification of Spp1 as the lead candidate at 
the neonatal timepoint.  This is an excellent candidate gene for left ventricular 
hypertrophy and will provide the basis for further functional and translational 
expetiments. 
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Appendix 
Table A.1 Primers name and oligonucleotide sequence 
Primer name  Oligonucleotide sequence 
Clock_1F    TTCGACAGGACTGGAAACCT 
Clock_1R    TGCGCTGTATAGTTCCTTCG 
Clock_2F    AGGAGCCATCCACCTATGAA 
Clock_2R    CCAAATCCACTGCTGTCCTT 
Clock_3F    GTCCTGGGAACATCAGGCTA 
Clock_3R    TGTGTGCGAGGACTTTCTTG 
Cxcl13_up_1F   CTCCCTTTTCCCCTCCTTTA 
Cxcl13_up_1R   ATCCTTTGTGCAGCTGTTCC 
Cxcl13_up_2F   GGCTAGAACTGCCAGACAGG 
Cxcl13_up_2R   CCATTGAGCTGACATGAACG 
Cxcl13_up_3F   CCTCGTTCATGTCAGCTCAA 
Cxcl13_up_3R   CTCACCCTTGGTAGGTGCTC 
Cxcl13_up_4F   CACCGAGGACTGAACACACA 
Cxcl13_up_4R   CCTTGGCAGAATCAACATCA 
Cxcl13_up_5F   AGAACTTGGTTGGCCTTTCA 
Cxcl13_up_5R   GCTGCGATGTCAGTTTTCAA 
Cxcl13_up_6F   TTTCACCCTCGAATCTCTGC 
Cxcl13_up_6R   AATGTTTTCACCCGCTTTTG 
Cxcl13_cDNA_1F   GGAGTCTGGAGCTGGAAACA 
Cxcl13_cDNA_1R   CCCAGGGCGTATAACTTGAA 
Cxcl13_cDNA_2F   CAAGTTATACGCCCTGGGAAT 
Cxcl13_cDNA_2R   GGAGCTTGGGGAGTTGAAGT 
Cxcl13_cDNA_3F    GCAGCCCTGCTTCTTCTACT 
Cxcl13_cDNA_3R    TAGCTTTCTTGGCCTTGGTC 
Cxcl13_3’UTR_1F    GCATGCCACAAGTTTTCCTT 
Cxcl13_3’UTR_1R    AGACCTGCTCTGCATCACCT 
Cxcl13_3’UTR_2F    GTCACCCCAAAAGACACCTG 
Cxcl13_3’UTR_2R    GGGTCACAGTGCAAAGGAAT 
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Primer name  Oligonucleotide sequence 
Spp1_up_AF    GCTCCAGCAZAATCTATTCC 
Spp1_up_BF    TCCTGTGGGCRCAGAGTAAAC 
Spp1_up_CF    CAAGACAATATTAAATATTT 
Spp1_up_DF    CTAAGTGAYTTGCCCAAGGT 
Spp1_up_AR    TGGCTGGCTTCCTCGAGAATG 
Spp1_up_AR    TGGCTGGCTTCCTCGAGAATG 
Spp1_AF    CATCCTTGGCTTTGCAGTCT 
Spp1_AR    AAACGTCTGCTTGTGTGCTG 
Spp1_BF    AAGCCTGACCCATCTCAGAA 
Spp1_BR    GCAACTGGGATGACCTTGAT 
Spp1_CF    GGAGTCCGATGAGGCTATCA 
Spp1_CR    TGAAACTCGTGGCTCTGATG 
Spp1_DF    CATCAGAGCCACGAGTTTCA 
Spp1_DR    TCAGGGCCCAAAACACTATC 
Spp1_EF    TGCTTGTTTCTCAGTTCAGTGG 
Spp1_ER    TCACACCAACAAAAATAATCACAA 
 
Table A.2 PCR product size 
The sizes in bp show the expected product size of the PCR reaction from Chapter 3 
Primer combination  Size in bp 
Clock 1F + 1R   432 
Clock 2F + 2R   437 
Clock 3F + 3R   420 
Cxcl13_cDNA_1F + 1R   234 
Cxcl13_cDNA_2F + 2R   155 
Cxcl13_up_1F + 1R  454 
Cxcl13_up_2F + 2R  473 
Cxcl13_up_3F + 3R  497 
Cxcl13_up_4F + 4R  402 
Cxcl13_up_5F + 5R  506 
Cxcl13_up_6F + 6R  463 
Cxcl13_3’UTR_1F + 1R  759 
Cxcl13_3’UTR_2F + 2R  618 
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Table A.3 PCR product size 
The sizes in bp show the expected product size of the PCR reaction from Chapter 4 
Primer combination  Size in bp 
Spp1_cDNA_AF + AR  459 
Spp1_cDNA_BF + BR  446 
Spp1_cDNA_BF + CR  713 
Spp1_cDNA_CF + DR  556 
Spp1_cDNA_DF + ER  531 
Spp1_cDNA_BF + DR  966 
Spp1_ups_AF + AR  2000 
Spp1_ups_BF + AR  1958 
Spp1_ups_CF + AR  1459 
Spp1_ups_DF + AR  1054 
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Figure A.1 Agilent analysis of RNA and cRNA used in the Illumina microarray 
A) Agilent analysis of RNA achieving an acceptable RIN and peak profile, allowing the 
samples to be used in IVT enzyme step.  B)  Agilent analysis of cRNA achieving an 
acceptable  bell  shaped  curved  as  stipulated  by  Illumina,  allowing  the  samples  to  be 
hybridized to the gene expression chip. 
A 
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Table A.4 Taqman gene expression assay probe ID’s 
The applied biosystems taqman probe ID’s for the gene expression assays in Chapter 3 & 4 
Gene  Taqman assay probe ID 
Spp1  Rn00681031_m1 
  Spp1  Rn00563571_m1) 
  Arhgap24   Rn01443832_m1 
Hsd17b13   Rn01450041_m1 
Rrad   Rn00584263_m1 
Cxcl13   Rn0140028_m1 
Abcg3   Rn01450015_m1 
Ccrl1   Rn01445226_m1   
Cxcr3   Rn00584589_m1 
Blr1 (Cxcr5)  Rn02132880_s1 
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Figure A.2 FDR report of the Genel level analysis of the Affymetrix exon array 
The FDR report shows the p-values for each of the pairwise comparisons in the analysis, 
filtered to the minimum congenic interval 29Mbp. 
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Figure A.3 FDR report of the Genel level analysis of the Illumina array 
The FDR report shows the p-values for each of the pairwise comparisons in the analysis of 
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